

Structural Guidelines for Stabilization of α -Helical Coiled Coils via PEG Stapling

Qiang Xiao, Zachary B. Jones, Samantha C. Hatfield, Dallin S. Ashton, Nicholas A. Dalley, Cody D. Dyer, Judah L. Evangelista, and Joshua L. Price*

Electronic Supplementary Information

1. Structures of coiled-coil and affibody variants.....	2
2. Synthesis of coiled-coil and affibody variants.....	10
3. Mass Spectrometry Data	11
4. Analytical HPLC data	42
5. Global Fitting of Variable Temperature CD Data	50
6. Proteolysis of coiled-coil variants	70
7. Fluorescence polarization binding assay.....	75
8. Stapling between heterochiral residues.....	77
9. Synthesis and Characterization of PEGylated Asparagine Derivatives, bis-azido PEG, branched Y-shaped bis-azido PEG.....	77

1. Structures of coiled-coil and affibody variants




Figure S1. Sequences of (A) acidic monomer **27e-z4**, basic monomer **29g'-x**, disulfide-bound coiled-coil heterodimer **d27e/29g'-z4x**, and its stapled counterpart **sd27e/29g'-z4x**. **X** represents propargyl glycine; **N** represents an azido-terminated PEG-modified Asn residue. Also shown are the structures of the side chains of **X** and **N** and their stapled counterpart superimposed on the ribbon diagram of parent disulfide-bonded heterodimer **A/B** (PDB ID: 1KD9). Side chains are shown as sticks; position **27e** is highlighted in orange, whereas position **29g'** is highlighted in blue. Variants **d27e/29g'-z4x** and **sd27e/29g'-z4x** are from reference ¹. The PEG oligomer(s) within each variant have the number of ethylene oxide units indicated in the structural drawings and in the compound names.




Figure S2. Sequences of (A) acidic monomer **20e-z4**, basic monomer **22g'-x**, disulfide-bound coiled-coil heterodimer **d20e/22g'-z4x**, and its stapled counterpart **sd20e/22g'-z4x**. **X** represents propargyl glycine; **N** represents an azido-terminated PEG-modified Asn residue. Also shown are the structures of the side chains of **X** and **N** and their stapled counterpart superimposed on the ribbon diagram of parent disulfide-bonded heterodimer **A/B** (PDB ID: 1KD9). Side chains are shown as sticks; position **20e** is highlighted in orange, whereas position **22g'** is highlighted in blue. The PEG oligomer(s) within each variant have the number of ethylene oxide units indicated in the structural drawings and in the compound names. Numbers in parentheses indicate notebook numbers associated with each compound.




Figure S3. Sequences of (A) acidic monomer **13e-z4**, basic monomer **15g'-x**, disulfide-bound coiled-coil heterodimer **d13e/15g'-z4x**, and its stapled counterpart **sd13e/15g'-z4x**. X represents propargyl glycine; N represents an azido-terminated PEG-modified Asn residue. Also shown are the structures of the side chains of X and N and their stapled counterpart superimposed on the ribbon diagram of parent disulfide-bonded heterodimer **A/B** (PDB ID: 1KD9). Side chains are shown as sticks; position **13e** is highlighted in orange, whereas position **15g'** is highlighted in blue. The PEG oligomer(s) within each variant have the number of ethylene oxide units indicated in the structural drawings and in the compound names. Numbers in parentheses indicate notebook numbers associated with each compound.




Figure S4. Sequences of (A) acidic monomer **6e-z4**, basic monomer **8g'-x**, disulfide-bound coiled-coil heterodimer **d6e/8g'-z4x**, and its stapled counterpart **sd6e/8g'-z4x**. X represents propargyl glycine; N represents an azido-terminated PEG-modified Asn residue. Also shown are the structures of the side chains of X and N and their stapled counterpart superimposed on the ribbon diagram of parent disulfide-bonded heterodimer **A/B** (PDB ID: 1KD9). Side chains are shown as sticks; position **6e** is highlighted in orange, whereas position **8g'** is highlighted in blue. The PEG oligomer(s) within each variant have the number of ethylene oxide units indicated in the structural drawings and in the compound names. Numbers in parentheses indicate notebook numbers associated with each compound.




Figure S5. Sequences of (A) acidic monomer **27e-z4**, basic monomer **22g'-x**, disulfide-bound coiled-coil heterodimer **d27e/22g'-z4x**, and its stapled counterpart **sd27e/22g'-z4x**. **X** represents propargyl glycine; **N** represents an azido-terminated PEG-modified Asn residue. Also shown are the structures of the side chains of **X** and **N** and their stapled counterpart superimposed on the ribbon diagram of parent disulfide-bonded heterodimer **A/B** (PDB ID: 1KD9). Side chains are shown as sticks; position **27e** is highlighted in orange, whereas position **22g'** is highlighted in blue. The PEG oligomer(s) within each variant have the number of ethylene oxide units indicated in the structural drawings and in the compound names. Numbers in parentheses indicate notebook numbers associated with each compound.




Figure S6. Sequences of (A) acidic monomer **6e-z4**, basic monomer **1g'-x**, disulfide-bound coiled-coil heterodimer **d6e/1g'-z4x**, and its stapled counterpart **sd6e/1g'-z4x**. **X** represents propargyl glycine; **N** represents an azido-terminated PEG-modified Asn residue. Also shown are the structures of the side chains of **X** and **N** and their stapled counterpart superimposed on the ribbon diagram of parent disulfide-bonded heterodimer **A/B** (PDB ID: 1KD9). Side chains are shown as sticks; position **6e** is highlighted in orange, whereas position **1g'** is highlighted in blue. The PEG oligomer(s) within each variant have the number of ethylene oxide units indicated in the structural drawings and in the compound names. Numbers in parentheses indicate notebook numbers associated with each compound.




Figure S7. Sequences of (A) acidic monomer **27e-z2**, basic monomer **29g'-x**, disulfide-bound coiled-coil heterodimer **d27e/29g'-z2x**, and its stapled counterpart **sd27e/29g'-z2x**. X represents propargyl glycine; N represents an azido-terminated PEG-modified Asn residue. Also shown are the structures of the side chains of X and N and their stapled counterpart superimposed on the ribbon diagram of parent disulfide-bonded heterodimer **A/B** (PDB ID: 1KD9). Side chains are shown as sticks; position **27e** is highlighted in orange, whereas position **29g'** is highlighted in blue. The PEG oligomer(s) within each variant have the number of ethylene oxide units indicated in the structural drawings and in the compound names. Numbers in parentheses indicate notebook numbers associated with each compound.




Figure S8. Sequences of (A) acidic monomer **27e-z2**, basic monomer **22g'-x**, disulfide-bound coiled-coil heterodimer **d27e/22g'-z2x**, and its stapled counterpart **sd27e/22g'-z2x**. X represents propargyl glycine; N represents an azido-terminated PEG-modified Asn residue. Also shown are the structures of the side chains of X and N and their stapled counterpart superimposed on the ribbon diagram of parent disulfide-bonded heterodimer **A/B** (PDB ID: 1KD9). Side chains are shown as sticks; position **27e** is highlighted in orange, whereas position **22g'** is highlighted in blue. The PEG oligomer(s) within each variant have the number of ethylene oxide units indicated in the structural drawings and in the compound names. Numbers in parentheses indicate notebook numbers associated with each compound.




Figure S9. Sequences of (A) acidic monomer **24b-z4**, basic monomer **25c'-x**, disulfide-bound coiled-coil heterodimer **d24b/25c'-z4x**, and its stapled counterpart **sd24b/25c'-z4x**. X represents propargyl glycine; N represents an azido-terminated PEG-modified Asn residue. Also shown are the structures of the side chains of X and N and their stapled counterpart superimposed on the ribbon diagram of parent disulfide-bonded heterodimer **A/B** (PDB ID: 1KD9). Side chains are shown as sticks; position **27e** is highlighted in blue, whereas position **29g'** is highlighted in orange. The PEG oligomer(s) within each variant have the number of ethylene oxide units indicated in the structural drawings and in the compound names. Numbers in parentheses indicate notebook numbers associated with each compound.




Figure S10. Sequences of (A) acidic monomer **7f-z4**, basic monomer **10b'-x**, disulfide-bound coiled-coil heterodimer **d7f/10b'-z4x**, and its stapled counterpart **sd7f/10b'-z4x**. X represents propargyl glycine; N represents an azido-terminated PEG-modified Asn residue. Also shown are the structures of the side chains of X and N and their stapled counterpart superimposed on the ribbon diagram of parent disulfide-bonded heterodimer **A/B** (PDB ID: 1KD9). Side chains are shown as sticks; position **7f** is highlighted in orange, whereas position **10b'** is highlighted in blue. The PEG oligomer(s) within each variant have the number of ethylene oxide units indicated in the structural drawings and in the compound names. Numbers in parentheses indicate notebook numbers associated with each compound.




Figure S11. Sequences of (A) acidic monomer **24b-z4**, basic monomer **25c'-y4**, disulfide-bound coiled-coil heterodimer **d24b/25c'-z4y4**, and its stapled counterpart **d24b/25c'-z4y4**. Z represents an alkyne-terminated PEG-modified Asn residue; N represents an azido-terminated PEG-modified Asn residue. Also shown are the structures of the side chains of Z and N and their stapled counterpart superimposed on the ribbon diagram of parent disulfide-bonded heterodimer **A/B** (PDB ID: 1KD9). Side chains are shown as sticks; position **24b** is highlighted in orange, whereas position **25c'** is highlighted in blue. The PEG oligomer(s) within each variant have the number of ethylene oxide units indicated in the structural drawings and in the compound names. Numbers in parentheses indicate notebook numbers associated with each compound.




Figure S12. Sequences of (A) acidic monomer **7f-z4**, basic monomer **10b'-y4**, disulfide-bound coiled-coil heterodimer **d7f/10b'-z4y4**, and its stapled counterpart **d7f/10b'-z4y4**. Z represents an alkyne-terminated PEG-modified Asn residue; N represents an azido-terminated PEG-modified Asn residue. Also shown are the structures of the side chains of Z and N and their stapled counterpart superimposed on the ribbon diagram of parent disulfide-bonded heterodimer **A/B** (PDB ID: 1KD9). Side chains are shown as sticks; position **7f** is highlighted in orange, whereas position **10b'** is highlighted in blue. The PEG oligomer(s) within each variant have the number of ethylene oxide units indicated in the structural drawings and in the compound names. Numbers in parentheses indicate notebook numbers associated with each compound.




Figure S13. Sequences of disulfide-bound coiled-coil heterodimer **d27e/29g'-xx**; its bis-triazole-stapled counterpart **sd27e/29g'-x4x**; branched PEG bis-triazole-stapled counterpart **sd27e/29g'-x4px**; and their component cysteine-containing acidic and basic monomers. **X** represents propargyl glycine; The structure of the **X** residues within each variant are shown in their non-stapled and stapled forms superimposed on the ribbon diagram of A/B with the residue on peptide A highlighted in orange and the residue on peptide B highlighted in blue. The PEG oligomer(s) within each variant have the number of ethylene oxide units indicated in the structural drawings and in the compound names. Numbers in parentheses indicate notebook numbers associated with each compound.




Figure S14. Sequences of native affibody **a** (PDB ID: 3MZW), non-stapled variant **a8/42-xx**; and its bis-triazole-stapled counterpart **sa8/42-x4x**. **X** represents propargyl glycine; The structure of the **X** residues within each variant are shown in their non-stapled and stapled forms superimposed on the ribbon diagram of **a** with position 8 highlighted in blue and position 42 highlighted in orange. The PEG oligomer staple has the number of ethylene oxide units indicated in the structural drawing and in the compound name. Numbers in parentheses indicate notebook numbers associated with each compound.

Modelling of z4x, z2x, z4y4, and x4x staples: We generated models for the z4x, z2x, z4y4, and x4x staples 2 in GaussView 6.0 based on the structures in main text Figure 2, but with *N*'-acetyl amino acid *N*-methyl amides on either end of the staple. We then optimized these model structure in Gaussian 16 using density functional theory (APFD) calculations with the 6-31G+d,p basis set. These optimized structures are shown below in Figure S15. We used the distance between the β -carbons on either end of each staple as an estimate of the distance that could be comfortably spanned by that staple. These distances appear in main text Table 1 and in ESI Table S2.




Figure S15. Drawings of staples z4x, z2x, x4x, and z4y4, along with ball-and-stick images of optimized model staples based on z4x, z2x, x4x, and z4y4. Models were built in GaussView 6.0 and optimized via DFT calculations (APFD) using the 6-31G+d,p basis set.

2. Synthesis of coiled-coil and affibody variants

Peptide Synthesis: Monomers **20e-z4** (ZJ10492); **22g'-x** (ZJ10452); **13e-z4** (ZJ10493); **15g'-x** (ZJ10494); **6e-z4** (DA10812, QX31101); **8g'-x** (DA10794); **27e-z4** (ZJ10311); **22g'-x** (ZJ10312); **1g'-x** (QX31102); **24b-z4** (DA10811, ND1095); **25c'-x** (DA10792); **25c'-y4** (QX3095); **7f-z4** (QX22951, QX30984); **10b'-x** (QX22952); **10b'-y4** (QX30982); **27e-z2** (DA10813, ZJ10313); **29g'-x** (DA10796, QX22712); **27e-x** (QX22711); and affibody variants **a** (CD1054) and **a8/42-xx** (QX3102) were prepared as C-terminal amides on Rink amide MBHA LL resin (EMD Biosciences), by microwave-assisted solid phase peptide synthesis using a standard Fmoc N α protection strategy as described previously.² Fmoc-protected amino acids were purchased from Advanced Chem Tech, except for the PEGylated asparagine derivatives, which were synthesized as described previously¹ or in section 7 below. Fluorescent affibody variants **fa** (ZJ10611); **fa8/42-xx** (ZJ10612); and **fsa8/42-x4x** (ZJ1062) were synthesized in a similar process until the final amino acid following which 5(6)-Carboxyfluorescein was coupled to the peptide N-terminus through activation with standard Oxyma/DIC protocols. Peptides were cleaved from resin and purified by preparative reverse-phase high-performance liquid chromatography (HPLC) on a C18 column using a linear gradient of water in acetonitrile with 0.1% v/v trifluoroacetic acid. Peptide identity was confirmed by electrospray ionization time- of-flight mass spectrometry.

Disulfide formation in the coiled-coil heterodimer: We prepared disulfide-bonded coiled-coil heterodimers **d20e/22g'-z4x** (ZJ10511); **d13e/15g'-z4x** (QX31171); **d6e/8g'-z4x** (QX2292); **d27e/22g'-z4x** (QX2294); **d6e/1g'-z4x** (QX31172); **d24b/25c'-z4x** (QX2291); **d24b/25c'-z4y4** (QX3096); **d7f/10b'-z4x** (QX2295); **d7f/10b'-z4y4** (QX3101); **d27e/29g'-z2x** (QX2289); **d27e/22g'-z2x** (QX2293); **d27e/29g'-xx** (QX2271) by mixing their purified cysteine-containing precursors in a 1:1 ratio in an aqueous solution of ammonium bicarbonate (8 mg/mL) with exposure to air for 3 hrs. Reaction completeness was monitored by analytical HPLC. Disulfide-bonded coiled-coil heterodimers were then purified by preparative HPLC and characterized by ESI-TOF MS.

Stapling via copper-catalyzed azide/alkyne cycloaddition (CuAAC): We prepared triazole-stapled variants **sd20e/22g'-z4x** (ZJ10511s); **sd13e/15g'-z4x** (QX31171s); **sd6e/8g'-z4x** (QX2292s); **sd27e/22g'-z4x** (QX2294s); **sd6e/1g'-z4x** (QX31172s); **sd24b/25c'-z4x** (QX2291s); **sd24b/25c'-z4y4** (QX3096s); **sd7f/10b'-z4x** (QX2295s); **sd7f/10b'-z4y4** (QX3101s); **sd27e/29g'-z2x** (QX2289s); **sd27e/22g'-z2x** (QX2293s) by stirring their purified non-stapled precursors in 2:1 (v/v) water/*tert*-butanol with 10 eq. copper sulfate pentahydrate and 10 eq. sodium ascorbate at 40 Celsius degree for 2 hours. The reaction was monitored by analytical HPLC, where we observed small changes in retention time upon stapling. The triazole-stapled variants were purified via preparative HPLC.

Two-component stapling via copper-catalyzed azide/alkyne cycloaddition (CuAAC): We prepared triazole-stapled variants **sd27e/29g'-x4x** (QX2283), **sa8/42-x4x** (QX3106), **fsa8/42-x4x** (ZJ1062), and **sd27e/29g'-x4px** (QX3079) by stirring their non-stapled precursors **d27e/29g'-xx** (QX2271), **a8/42-xx** (QX3102), and **fa8/42-xx** (ZJ10612), respectively, in 2:1 (v/v) water/*tert*-butanol with 1.5 eq. of previously synthesized four-unit bis-azido PEG **4**¹ or four-unit bis-azido Y-shaped PEG **4p** (QX3075; synthesis described in section 10 below), 10 eq. copper sulfate pentahydrate and 10 eq. sodium ascorbate at 40 °C for 2 hours. The reaction was monitored by analytical HPLC, where we observed small changes in retention time upon stapling. The triazole-stapled variants were purified via preparative HPLC.

The CuAAC reaction does not change the mass of the monomeric triazole-stapled variants **sd20e/22g'-z4x** (ZJ10511s); **sd13e/15g'-z4x** (QX31171s); **sd6e/8g'-z4x** (QX2292s); **sd27e/22g'-z4x** (QX2294s); **sd6e/1g'-z4x** (QX31172s); **sd24b/25c'-z4x** (QX2291s); **sd24b/25c'-z4y4** (QX3096s); **sd7f/10b'-z4x** (QX2295s); **sd7f/10b'-z4y4** (QX3101s); **sd27e/29g'-z2x** (QX2289s); **sd27e/22g'-z2x** (QX2293s) relative to their non-stapled azide/alkyne precursors **d20e/22g'-z4x** (ZJ10511); **d13e/15g'-z4x** (QX31171); **d6e/8g'-z4x** (QX2292); **d27e/22g'-z4x** (QX2294); **d6e/1g'-z4x** (QX31172); **d24b/25c'-z4x** (QX2291); **d24b/25c'-z4y4** (QX3096); **d7f/10b'-z4x** (QX2295); **d7f/10b'-z4y4** (QX3101); **d27e/29g'-z2x** (QX2289); and **d27e/22g'-z2x** (QX2293). To confirm the completion of the CuAAC reaction, we subjected each azide-containing non-stapled variant and its triazole-stapled counterpart separately to a solution of dithiothreitol (DTT, 15 mg) in 100 µL water, followed by incubation at room temperature for 8 hours. In all cases, the unstapled variants were reduced to their corresponding monomers with DTT addition, for the triazole-stapled variants, the dimer still existed as dimer after the DTT treatment, indicating the formation of covalent linkage between monomers.

3. Mass Spectrometry Data

Mass spectra appear in Figures S16–S84; data are summarized in Table S1.

Table S1. Summary of the mass spectrum data for stapled disulfide-bonded coiled-coil heterodimers, their non-stapled counterparts, and their monomer components.

Name	Notebook Number	Molecular Formula	z	Expected [M+z·H]/z	Observed [M+z·H]/z
20e-z4	ZJ10492	C ₁₈₅ H ₂₉₅ N ₅₁ O ₆₈ S	4	1088.781	1088.770
22g'-x	ZJ10452	C ₁₈₇ H ₃₂₄ N ₅₆ O ₄₆ S	4	1031.620	1031.596
d20e/22g'-z4x	ZJ10511	C ₃₇₂ H ₆₁₇ N ₁₀₇ O ₁₁₄ S ₂	8	1059.948	1060.066
sd20e/22g'-z4x	ZJ10511s	C ₃₇₂ H ₆₁₇ N ₁₀₇ O ₁₁₄ S ₂	8	1059.948	1060.086
	ZJ10511s + DTT	C ₃₇₂ H ₆₁₉ N ₁₀₇ O ₁₁₄ S ₂	8	1060.200	1060.572
13e-z4	ZJ10493	C ₁₈₅ H ₂₉₅ N ₅₁ O ₆₈ S	4	1088.781	1088.763
15g'-x	ZJ10494	C ₁₈₇ H ₃₂₄ N ₅₆ O ₄₆ S	4	1031.620	1031.601
d13e/15g'-z4x	QX31171	C ₃₇₂ H ₆₁₇ N ₁₀₇ O ₁₁₄ S ₂	8	1059.948	1060.086
sd13e/15g'-z4x	QX31171s	C ₃₇₂ H ₆₁₇ N ₁₀₇ O ₁₁₄ S ₂	7	1211.225	1211.195
	+ DTT	C ₃₇₂ H ₆₁₉ N ₁₀₇ O ₁₁₄ S ₂	8	1060.200	1060.851
6e-z4	DA10812	C ₁₈₅ H ₂₉₅ N ₅₁ O ₆₈ S	4	1088.781	1088.783
8g'-x	DA10794	C ₁₈₇ H ₃₂₄ N ₅₆ O ₄₆ S	4	1031.620	1031.619
d6e/8g'-z4x	QX2292	C ₃₇₂ H ₆₁₇ N ₁₀₇ O ₁₁₄ S ₂	8	1059.948	1059.948
sd6e/8g'-z4x	QX2292s	C ₃₇₂ H ₆₁₇ N ₁₀₇ O ₁₁₄ S ₂	6	1415.928	1412.937
	QX2292s + DTT	C ₃₇₂ H ₆₁₉ N ₁₀₇ O ₁₁₄ S ₂	8	1060.200	1060.074
27e-z4	ZJ10311	C ₁₈₅ H ₂₉₅ N ₅₁ O ₆₈ S	4	1088.781	1088.781
22g'-x	ZJ10312	C ₁₈₇ H ₃₂₄ N ₅₆ O ₄₆ S	4	1031.620	1031.613
d27e/22g'-z4x	QX2294	C ₃₇₂ H ₆₁₇ N ₁₀₇ O ₁₁₄ S ₂	8	1059.948	1059.953
sd27e/22g'-z4x	QX2294s	C ₃₇₂ H ₆₁₇ N ₁₀₇ O ₁₁₄ S ₂	8	1059.948	1059.953
	QX2294s + DTT	C ₃₇₂ H ₆₁₉ N ₁₀₇ O ₁₁₄ S ₂	8	1060.200	1060.197
6e-z4	QX31101	C ₁₈₅ H ₂₉₅ N ₅₁ O ₆₈ S	4	1088.781	1088.789
1g'-x	QX31102	C ₁₈₇ H ₃₂₄ N ₅₆ O ₄₆ S	4	1031.620	1031.629
d6e/1g'-z4x	QX31172	C ₃₇₂ H ₆₁₇ N ₁₀₇ O ₁₁₄ S ₂	8	1059.948	1060.088
sd6e/1g'-z4x	QX31172s	C ₃₇₂ H ₆₁₇ N ₁₀₇ O ₁₁₄ S ₂	7	1211.225	1211.388
	+ DTT	C ₃₇₂ H ₆₁₉ N ₁₀₇ O ₁₁₄ S ₂	7	1211.513	1211.291
27e-z2	DA10813	C ₁₈₃ H ₂₉₀ N ₄₈ O ₆₇ S	4	1066.768	1066.763
29g'-x	DA10796	C ₁₈₇ H ₃₂₄ N ₅₆ O ₄₆ S	4	1031.620	1031.622
d27e/29g'-z2x	QX2289	C ₃₆₈ H ₆₀₉ N ₁₀₇ O ₁₁₂ S ₂	8	1048.942	1048.940
sd27e/29g'-z2x	QX2289s	C ₃₆₈ H ₆₀₉ N ₁₀₇ O ₁₁₂ S ₂	8	1048.942	1048.942
	QX2289s + DTT	C ₃₆₈ H ₆₁₁ N ₁₀₇ O ₁₁₂ S ₂	8	1049.194	1049.326
27e-z2	ZJ10313	C ₁₈₁ H ₂₈₆ N ₅₁ O ₆₆ S	4	1066.768	1066.769
22g'-x	ZJ10312	C ₁₈₇ H ₃₂₄ N ₅₆ O ₄₆ S	4	1031.620	1031.613
d27e/22g'-z2x	QX2293	C ₃₆₈ H ₆₀₉ N ₁₀₇ O ₁₁₂ S ₂	8	1048.942	1048.948
sd27e/22g'-z2x	QX2293s	C ₃₆₈ H ₆₀₉ N ₁₀₇ O ₁₁₂ S ₂	8	1048.942	1048.948
	QX2293s + DTT	C ₃₆₈ H ₆₁₁ N ₁₀₇ O ₁₁₂ S ₂	8	1049.194	1049.067
24b-z4	DA10811	C ₁₈₇ H ₂₉₇ N ₅₁ O ₇₀ S	4	1103.282	1103.268
25c'-x	DA10792	C ₁₈₇ H ₃₂₄ N ₅₄ O ₄₆ S	4	1024.618	1024.605
d24b/25c'-z4x	QX2291	C ₃₇₄ H ₆₁₉ N ₁₀₅ O ₁₁₆ S ₂	8	1063.698	1063.705
sd24b/25c'-z4x	QX2291s	C ₃₇₄ H ₆₁₉ N ₁₀₅ O ₁₁₆ S ₂	8	1063.698	1063.697
	QX2291s + DTT	C ₃₇₄ H ₆₂₁ N ₁₀₅ O ₁₁₆ S ₂	8	1063.950	1063.950
24b-z4	ND1095	C ₁₈₇ H ₂₉₇ N ₅₁ O ₇₀ S	4	1103.282	1103.268
25c'-y4	QX3095	C ₁₉₇ H ₃₄₃ N ₅₅ O ₅₁ S	4	1082.900	1082.906
d24b/25c'-z4y4	QX3096	C ₃₈₄ H ₆₃₈ N ₁₀₆ O ₁₂₁ S ₂	8	1092.839	1093.064
sd24b/25c'-z4y4	QX3096s	C ₃₈₄ H ₆₃₈ N ₁₀₆ O ₁₂₁ S ₂	8	1092.839	1093.072
	QX3096s + DTT	C ₃₈₄ H ₆₄₀ N ₁₀₆ O ₁₂₁ S ₂	8	1093.091	1093.315
7f-z4	QX22951	C ₁₈₇ H ₂₉₇ N ₅₁ O ₇₀ S	4	1103.282	1103.298
10b'-x	QX22952	C ₁₈₈ H ₃₂₉ N ₅₇ O ₄₄ S	4	1031.383	1031.397
d7f/10b'-z4x	QX2295	C ₃₇₅ H ₆₂₄ N ₁₀₈ O ₁₁₄ S ₂	8	1067.081	1067.088
sd7f/10b'-z4x	QX2295s	C ₃₇₅ H ₆₂₄ N ₁₀₈ O ₁₁₄ S ₂	7	1219.377	1219.364
	QX2295s + DTT	C ₃₇₅ H ₆₂₆ N ₁₀₈ O ₁₁₄ S ₂	7	1219.665	1219.807
7f-z4	QX30984	C ₁₈₇ H ₂₉₇ N ₅₁ O ₇₀ S	4	1103.282	1103.298
10b'-y4	QX30982	C ₁₉₈ H ₃₄₈ N ₅₈ O ₄₉ S	4	1089.664	1089.671
d7f/10b'-z4y4	QX3101	C ₃₈₅ H ₆₄₃ N ₁₀₉ O ₁₁₉ S ₂	8	1096.221	1096.447
sd7f/10b'-z4y4	QX3101s	C ₃₈₅ H ₆₄₃ N ₁₀₉ O ₁₁₉ S ₂	7	1252.680	1253.046
	QX3101s + DTT	C ₃₈₅ H ₆₄₅ N ₁₀₉ O ₁₁₉ S ₂	8	1096.473	1096.697
27e-x	QX22711	C ₁₇₈ H ₂₇₉ N ₄₇ O ₆₄ S	4	1033.752	1033.757
29g-x	QX22712	C ₁₈₇ H ₃₂₄ N ₅₆ O ₄₆ S	4	1031.620	1031.624

d27e/29g'-xx	QX2271	C ₃₆₅ H ₆₀₁ N ₁₀₃ O ₁₁₀ S ₂	8	1032.434	1032.442
sd27e/29g'-x4x	QX2283	C ₃₇₃ H ₆₁₇ N ₁₀₉ O ₁₁₃ S ₂	8	1062.950	1062.953
	QX2283 + DTT	C ₃₇₃ H ₆₁₉ N ₁₀₉ O ₁₁₃ S ₂	8	1063.202	1063.33
sd27e/29g'-x4px	QX3079	C ₃₈₃ H ₆₃₆ N ₁₁₀ O ₁₁₈ S ₂	8	1092.090	1092.075
	QX3079 + DTT	C ₃₈₃ H ₆₃₈ N ₁₁₀ O ₁₁₈ S ₂	8	1092.342	1092.447
(R)-27e-x	ZJ10551	C ₁₇₈ H ₂₇₉ N ₄₇ O ₆₄ S	4	1033.752	1033.751
(R,S)-d27e/29g'-xx	QX3118	C ₃₆₅ H ₆₀₁ N ₁₀₃ O ₁₁₀ S ₂	8	1032.434	1032.541
(R,S)-sd27e/29g'-x4x	ZJ1056	C ₃₇₃ H ₆₁₇ N ₁₀₉ O ₁₁₃ S ₂	8	1062.950	1063.073
	ZJ1056 + DTT	C ₃₇₃ H ₆₁₉ N ₁₀₉ O ₁₁₃ S ₂	8	1063.202	1063.264
affibody a	CD1054	C ₂₉₆ H ₄₇₁ N ₈₇ O ₈₉ S	5	1341.103	1341.106
a8/42-xx	QX3102	C ₂₉₈ H ₄₆₉ N ₈₇ O ₈₇ S	5	1339.102	1339.123
sa8/42-x4x	QX3106	C ₃₀₆ H ₄₈₅ N ₉₃ O ₉₀ S	5	1387.927	1387.915
Fluorescent affibody fa	ZJ10611	C ₃₁₇ H ₄₈₀ N ₈₆ O ₉₅ S	5	1412.914	1412.883
fa8/42-xx	ZJ01612	C ₃₁₉ H ₄₇₈ N ₈₆ O ₉₃ S	5	1410.913	1410.888
fsa8/42-x4x	ZJ1062	C ₃₂₇ H ₄₉₄ N ₉₂ O ₉₆ S	5	1459.738	1459.705




Figure S16. ESI-TOF spectrum for acidic monomer **20e-z4** (ZJ10492, C₁₈₅H₂₉₅N₅₁O₆₈S). Expected [M+4H⁺]/4 = 1088.781 Da. Observed [M+4H⁺]/4 = 1088.770 Da.




Figure S17. ESI-TOF spectrum for basic monomer **22g'-x** (ZJ10452, C₁₈₇H₃₂₄N₅₆O₄₆S). Expected [M+4H⁺]/4 = 1031.620 Da. Observed [M+4H⁺]/4 = 1031.596 Da.




Figure S18. ESI-TOF spectrum for disulfide-bound coiled-coil variant **d20e/22g'-z4x** (ZJ10511, C₃₇₂H₆₁₇N₁₀₇O₁₁₄S₂). Expected [M+8H⁺]/8 = 1059.948 Da. Observed [M+8H⁺]/4 = 1060.067 Da.





Figure S19. ESI-TOF spectrum for disulfide-bound stapled coiled-coil variant **sd20e/22g'-z4x** (ZJ10511s, C₃₇₂H₆₁₇N₁₀₇O₁₁₄S₂). Expected [M+8H⁺]/8 = 1059.948 Da. Observed [M+8H⁺]/4 = 1060.086 Da.






Figure S21. ESI-TOF spectrum for acidic monomer **13e-z4** (ZJ10493, C₁₈₅H₂₉₅N₅₁O₆₈S). Expected [M+4H⁺]/4 = 1088.781 Da. Observed [M+4H⁺]/4 = 1088.763 Da.




Figure S22. ESI-TOF spectrum for basic monomer **15g'-x** (ZJ10494, C₁₈₇H₃₂₄N₅₆O₄₆S). Expected [M+4H⁺]/4 = 1031.620 Da. Observed [M+4H⁺]/4 = 1031.601 Da.




Figure S23. ESI-TOF spectrum for disulfide-bound coiled-coil variant **d13e/15g'-z4x** (QX31171, C₃₇₂H₆₁₇N₁₀₇O₁₁₄S₂). Expected [M+8H⁺]/8 = 1059.948 Da. Observed [M+4H⁺]/4 = 1060.086 Da.




Figure S24. ESI-TOF spectrum for stapled disulfide-bound coiled-coil variant **sd13e/15g'-z4x** (QX31171s, C₃₇₂H₆₁₇N₁₀₇O₁₁₄S₂). Expected [M+7H⁺]/7 = 1211.225 Da. Observed [M+7H⁺]/7 = 1211.195 Da.




Figure S25. ESI-TOF MS data for azide-containing (A) disulfide-bound coiled-coil variant **d13e/15g'-z4x** before (QX31171; C₃₇₂H₆₁₇N₁₀₇O₁₁₄S₂; expected [M+8H⁺]/8 = 1059.948 Da) and (B) after exposure to reducing conditions (1M DTT) for at least 8h. Following reduction, **d13e/15g'-z4x** splits into its component peptides: **13e-z4** (ZJ10493; C₁₈₅H₂₉₅N₅₁O₆₈S; expected mass [M+4H⁺]/4 = 1088.781 Da) and **15g'-x** (ZJ10494; C₁₈₇H₃₂₄N₅₆O₄₆S; expected mass [M+4H⁺]/4 = 1031.620 Da). **15g'-x** does not appear in spectrum for reasons that are not clear. Instead, we observe a peak with m/z = 1109.117 Da and isotopic spacing consistent with z = 4. This peak is consistent with bis-DTT adduct of **15g'-x** (C₁₉₅H₃₄₄N₅₆O₅₀S₅; expected [M+4H⁺]/4 = 1108.626), which could be formed via tandem thiol-yne and thiol-ene reactions between the propargylglycine of **15g'-x** and two equivalents of DTT. Also shown are ESI-TOF MS data for (C) triazole-stapled coiled-coil variant **sd13e/15g'-z4x** before (QX31171s; C₃₇₂H₆₁₇N₁₀₇O₁₁₄S₂; expected [M+7H⁺]/7 = 1211.225 Da) and (E) after exposure to reduction conditions for at least 8h (C₃₇₂H₆₁₉N₁₀₇O₁₁₄S₂; expected [M+8H⁺]/8 = 1060.200 Da after reduction of disulfide bond to cysteine residues). Note that **sd13e/15g'-z4x** remains intact even after disulfide reduction due to the triazole staple.




Figure S26. ESI-TOF spectrum for acidic monomer **6e-z4** (DA10812; $C_{185}H_{295}N_{51}O_{68}S$; expected $[M+4H^+]/4 = 1088.781$ Da. Observed $[M+4H^+]/4 = 1088.783$ Da.




Figure S27. ESI-TOF spectrum for basic variant **8g'-x** (DA10794; $C_{187}H_{324}N_{56}O_{46}S$). Expected $[M+4H^+]/4 = 1031.620$ Da. Observed $[M+4H^+]/4 = 1031.619$ Da.




Figure S28. ESI-TOF spectrum for disulfide-bound coiled-coil variant **d6e/8g'-z4x** (QX2292; $C_{372}H_{617}N_{107}O_{114}S_2$). Expected $[M+8H^+]/8 = 1059.948$ Da. Observed $[M+8H^+]/8 = 1059.948$ Da.




Figure S29. ESI-TOF spectrum for stapled disulfide-bound coiled-coil variant **sd6e/8g'-z4x** (QX2292s; $C_{372}H_{617}N_{107}O_{114}S_2$). Expected $[M+6H^+]/6 = 1412.928$ Da. Observed $[M+6H^+]/6 = 1412.937$ Da.




Figure S30. ESI-TOF MS data for (A) disulfide-bound coiled-coil variant **d6e/8g'-z4x** before (QX2292; C₃₇₂H₆₁₇N₁₀₇O₁₁₄S₂; expected $[M+8H^+]/8 = 1059.948$ Da) and (B,C) after exposure to reducing conditions (1M DTT) for at least 8h. Following reduction, **d6e/8g'-z4x** should split into its component peptides: **6e-z4** (DA10812; C₁₈₅H₃₂₄N₅₆O₆₈S; expected mass $[M+4H^+]/4 = 1088.781$) and **8g'-x** (DA10794; C₁₈₇H₃₂₄N₅₆O₄₆S; expected mass $[M+4H^+]/4 = 1031.620$ Da). Peptide **8g'-x** does not appear in (B,C) for reasons that are unclear. Also shown are ESI-TOF MS data for (D) triazole-stapled **sd6e/8g'-z4x** before (QX2292s; C₃₇₂H₆₁₇N₁₀₇O₁₁₄S₂; expected $[M+6H^+]/6 = 1412.928$ Da) and (E,F) after exposure to reducing conditions (1M DTT) for at least 8h (C₃₇₂H₆₁₉N₁₀₇O₁₁₄S₂; expected $[M+8H^+]/8 = 1060.200$ Da after reduction of disulfide bond to free cysteine residues). Note that **sd6e/8g'-z4x** remains intact even after disulfide reduction due to the triazole staple.




Figure S31. ESI-TOF spectrum for acidic monomer **27e-z4** (ZJ10311, C₁₈₅H₂₉₅N₅₁O₆₈S). Expected [M+4H⁺]/4 = 1088.781 Da. Observed [M+4H⁺]/4 = 1088.781 Da.




Figure S32. ESI-TOF spectrum for basic monomer **22g'-x** (ZJ10312, C₁₈₇H₃₂₄N₅₆O₄₆S). Expected [M+4H⁺]/4 = 1031.620 Da. Observed [M+4H⁺]/4 = 1031.613 Da.




Figure S33. ESI-TOF spectrum for disulfide-bound coiled-coil variant **d27e/22g'-z4x** (QX2294, C₃₇₂H₆₁₇N₁₀₇O₁₁₄S₂). Expected [M+8H⁺]/8 = 1059.948 Da. Observed [M+8H⁺]/8 = 1059.953 Da.




Figure S34. ESI-TOF spectrum for stapled disulfide-bound coiled-coil variant **sd27e/22g'-40** (QX2294s, C₃₇₂H₆₁₇N₁₀₇O₁₁₄S₂). Expected [M+8H⁺]/8 = 1059.948 Da. Observed [M+8H⁺]/8 = 1059.953 Da




Figure S35. ESI-TOF MS data for azide-containing (A) disulfide-bound coiled-coil variant **d27e/22g'-z4x** before (QX2294; $C_{372}H_{617}N_{107}O_{114}S_2$; expected $[M+8H^+]/8 = 1059.948$ Da) and (B,C) after exposure to reducing conditions (1M DTT) for at least 8h. Following reduction, **d27e/22g'-z4x** splits into its component peptides: **27e-z4** (ZJ10311; $C_{187}H_{324}N_{56}O_{46}S$; expected mass $[M+4H^+]/4 = 1088.781$ Da) and **22g'-x** (ZJ10312; $C_{187}H_{324}N_{56}O_{46}S$; expected mass $[M+4H^+]/4 = 1031.620$ Da; does not appear in spectrum for reasons that are not clear). Also shown are ESI-TOF MS data for (D) triazole-stapled disulfide-bound coiled-coil variant **sd27e/22g'-z4x** before (QX2294s; $C_{372}H_{617}N_{107}O_{114}S_2$; expected $[M+8H^+]/8 = 1059.948$ Da) and (E,F) after exposure to reduction conditions for at least 8h ($C_{372}H_{619}N_{107}O_{114}S_2$; expected $[M+8H^+]/8 = 1060.073$ Da after reduction of disulfide bond to cysteine residues). Note that **sd27e/22g'-z4x** remains intact even after disulfide reduction due to the triazole staple.




Figure S36. ESI-TOF spectrum for acidic monomer **6e-z4** (QX31101, $C_{185}H_{295}N_{51}O_{68}S$). Expected $[M+4H^+]/4 = 1088.781$ Da. Observed $[M+4H^+]/4 = 1088.789$ Da.




Figure S37. ESI-TOF spectrum for basic monomer **1g'-x** (QX31102, $C_{187}H_{324}N_{56}O_{46}S$). Expected $[M+4H^+]/4 = 1031.620$ Da. Observed $[M+4H^+]/4 = 1031.629$ Da.




Figure S38. ESI-TOF spectrum for disulfide-bound coiled-coil variant **d6e/1g'-z4x** (QX31172, $C_{372}H_{617}N_{107}O_{114}S_2$). Expected $[M+8H^+]/8 = 1059.948$ Da. Observed $[M+4H^+]/4 = 1060.088$ Da.




Figure S39. ESI-TOF spectrum for stapled disulfide-bound coiled-coil variant **sd6e/1g'-z4x** (QX31172s, $C_{372}H_{617}N_{107}O_{114}S_2$). Expected $[M+7H^+]/7 = 1211.225$ Da. Observed $[M+7H^+]/7 = 1211.388$ Da.




Figure S40. ESI-TOF MS data for azide-containing (A) disulfide-bound coiled-coil variant **d6e/1g'-z4x** before (QX31172; $C_{372}H_{617}N_{107}O_{114}S_2$; expected $[M+8H^+]_8 = 1059.948$ Da) and (B,C) after exposure to reducing conditions (1M DTT) for at least 8h. Following reduction, **d6e/1g'-z4x** splits into its component peptides: **6e-z4** (QX31101; $C_{185}H_{295}N_{51}O_{68}S$; expected mass $[M+4H^+]_4 = 1088.781$ Da) and **1g'-x** (QX31102; $C_{187}H_{324}N_{56}O_{46}S$; expected mass $[M+4H^+]_4 = 1031.620$ Da; does not appear in spectrum for reasons that are not clear). Also shown are ESI-TOF MS data for (D) triazole-stapled disulfide-bound coiled-coil variant **sd6e/1g'-z4x** before (QX31172s; $C_{372}H_{617}N_{107}O_{114}S_2$; expected $[M+7H^+]_7 = 1211.225$ Da) and (E,F) after exposure to reduction conditions for at least 8h ($C_{372}H_{619}N_{107}O_{114}S_2$; expected $[M+7H^+]_7 = 1211.513$ Da after reduction of disulfide bond to cysteine residues). Note that **sd6e/1g'-z4x** remains intact even after disulfide reduction due to the triazole staple.




Figure S41. ESI-TOF spectrum for acidic monomer **27e-z2** (DA10813; $C_{183}H_{290}N_{48}O_{67}S$; expected $[M+4H^+]/4 = 1066.768$ Da). Observed $[M+4H^+]/4 = 1066.763$ Da.




Figure S42. ESI-TOF spectrum for basic monomer **29g'-x** (DA10796; $C_{187}H_{324}N_{56}O_{46}S$; expected $[M+4H^+]/4 = 1031.620$ Da). Observed $[M+4H^+]/4 = 1031.622$ Da.




Figure S43. ESI-TOF spectrum for disulfide-bound coiled-coil variant **d27e/29g'-z2x** (QX2289; $C_{368}H_{609}N_{107}O_{112}S_2$; expected $[M+8H^+]/8 = 1048.942$ Da). Observed $[M+8H^+]/8 = 1048.940$ Da.




Figure S44. ESI-TOF spectrum for coiled-coil variant **sd27e/29g'-z2x** (QX2289s; $C_{368}H_{609}N_{107}O_{112}S_2$; expected $[M+8H^+]/8 = 1048.942$ Da). Observed $[M+8H^+]/8 = 1048.942$ Da.




Figure S45. ESI-TOF MS data for (A) coiled-coil variant **d27e/29g'-z2x** before (QX2289; C₃₆₈H₆₀₉N₁₀₇O₁₁₂S₂; expected [M+8H⁺]/8 = 1048.942 Da) and (B,C) after exposure to reducing conditions (1M DTT) for at least 8h. Following reduction, **d27e/29g'-z2x** splits into its component peptides: **27e-z2** (DA10813; C₁₈₃H₂₉₀N₄₈O₆₇S; expected mass [M+4H⁺]/4 = 1066.7682) and **29g'-x** (DA10796; C₁₈₇H₃₂₄N₅₆O₄₆S; expected mass [M+4H⁺]/4 = 1031.620 Da). Also shown are ESI-TOF MS data for (D) triazole-stapled **sd27e/29g'-z2x** before (QX2289s; C₃₆₈H₆₀₉N₁₀₇O₁₁₂S₂; expected [M+8H⁺]/8 = 1048.942 Da) and (E,F) after exposure to reducing conditions (1M DTT) for at least 8h (C₃₇₃H₆₁₉N₁₀₉O₁₁₃S₂; expected [M+8H⁺]/8 = 1049.194 Da after reduction of disulfide bond to free cysteine residues). Note that **sd27e/29g'-z2x** remains intact even after disulfide reduction due to the triazole staple.




Figure S46. ESI-TOF spectrum for acidic monomer **27e-z2** (ZJ10313; $C_{181}H_{286}N_{51}O_{66}S$; expected $[M+4H^+]/4 = 1066.768$ Da). Observed $[M+4H^+]/4 = 1066.769$ Da.




Figure S47. ESI-TOF spectrum for basic monomer **22g'-x** (ZJ10312; $C_{187}H_{324}N_{56}O_{46}S$; expected $[M+4H^+]/4 = 1031.620$ Da). Observed $[M+4H^+]/4 = 1031.613$ Da.




Figure S48. ESI-TOF spectrum for disulfide-bound coiled-coil variant **d27e/22g'-z2x** (QX2293; $C_{368}H_{609}N_{107}O_{112}S_2$; expected $[M+8H^+]/8 = 1048.942$ Da). Observed $[M+8H^+]/8 = 1048.948$ Da.




Figure S49. ESI-TOF spectrum for stapled disulfide-bound coiled-coil variant **sd27e/22g'-z2x** (QX2293s; $C_{368}H_{609}N_{107}O_{112}S_2$; expected $[M+8H^+]/8 = 1048.942$ Da). Observed $[M+8H^+]/8 = 1048.948$ Da.




Figure S50. ESI-TOF MS data for (A) coiled-coil variant **d27e/22g'-z2x** before (QX2293; $C_{368}H_{609}N_{107}O_{112}S_2$; expected $[M+8H^+]/8 = 1048.942$ Da) and (B,C) after exposure to reducing conditions (1M DTT) for at least 8h. Following reduction, **d27e/22g'-z2x** splits into its component peptides: **27e-z2** (ZJ10313; $C_{181}H_{286}N_{51}O_{66}S$; expected mass $[M+4H^+]/4 = 1066.768$) and **22g'-x** (ZJ10312; $C_{187}H_{324}N_{56}O_{46}S$; expected mass $[M+4H^+]/4 = 1031.620$ Da). Also shown are ESI-TOF MS data for (D) triazole-stapled **sd27e/22g'-z2x** before (QX2293s; $C_{368}H_{609}N_{107}O_{112}S_2$; expected $[M+8H^+]/8 = 1048.942$ Da) and (E,F) after exposure to reducing conditions (1M DTT) for at least 8h ($C_{368}H_{611}N_{107}O_{112}S_2$; expected $[M+8H^+]/8 = 1049.194$ Da after reduction of disulfide bond to free cysteine residues). Note that **sd27e/22g'-z2x** remains intact even after disulfide reduction due to the triazole staple.




Figure S51. ESI-TOF spectrum for acidic monomer **24b-z4** (DA10811, $C_{187}H_{297}N_{51}O_{70}S$). Expected $[M+4H^+]/4 = 1103.282$ Da. Observed $[M+4H^+]/4 = 1103.268$ Da.




Figure S52. ESI-TOF spectrum for basic monomer **25c'-x** (DA10792; $C_{187}H_{324}N_{54}O_{46}S$). Expected $[M+4H^+]/4 = 1024.618$ Da. Observed $[M+4H^+]/4 = 1024.605$ Da.




Figure S53. ESI-TOF spectrum for disulfide-bound coiled-coil variant **d24b/25c'-z4x** (QX2291, $C_{374}H_{619}N_{105}O_{116}S_2$). Expected $[M+8H^+]/8 = 1063.698$ Da. Observed $[M+8H^+]/8 = 1063.705$ Da.




Figure S54. ESI-TOF spectrum for stapled disulfide-bound coiled-coil variant **sd24b/25c'-z4x** (QX2291s, $C_{374}H_{619}N_{105}O_{116}S_2$). Expected $[M+8H^+]/8 = 1063.698$ Da. Observed $[M+8H^+]/8 = 1063.697$ Da.




Figure S55. ESI-TOF MS data for (A) disulfide-bound coiled-coil variant **d24b/25c'-z4x** before (QX2291; C₃₇₄H₆₁₉N₁₀₅O₁₁₆S₂; expected [M+8H⁺]/8 = 1063.698 Da) and (B,C) after exposure to reducing conditions (1M DTT) for at least 8h. Following reduction, **d24b/25c'-z4x** should split into its component peptides: **24b-z4** (DA10811; C₁₈₇H₂₉₇N₅₁O₇₀S; expected mass [M+4H⁺]/4 = 1103.282) and **25c'-x** (DA10792; C₁₈₇H₃₂₄N₅₄O₄₆S; expected mass [M+4H⁺]/4 = 1024.618 Da). However, neither of these appear in (B,C). Instead, we observe a peak with m/z = 1101.628 Da and isotopic spacing consistent with z = 4. This peak is consistent with bis-DTT adduct of **25c'-x** (C₁₉₅H₃₄₄N₅₄O₅₀S₅; expected [M+4H⁺]/4 = 1101.624), which could be formed via tandem thiol-yne and thiol-ene reactions between the propargylglycine of **25c'-x** and two equivalents of DTT. Peptide **24b-4** does not appear in (B,C) for reasons that are unclear. Also shown are ESI-TOF MS data for (D) triazole-stapled disulfide-bound coiled-coil variant **sd24b/25c'-z4x** before (QX2291s; C₃₇₄H₆₁₉N₁₀₅O₁₁₆S₂; expected [M+8H⁺]/8 = 1063.698 Da and (E,F) after exposure to reducing conditions (1M DTT) for at least 8h (C₃₇₄H₆₂₁N₁₀₅O₁₁₆S₂; expected [M+8H⁺]/8 = 1063.950 Da after reduction of disulfide bond to free cysteine residues). Note that **sd24b/25c'-z4x** remains intact even after disulfide reduction due to the triazole staple.




Figure S56. ESI-TOF spectrum for basic monomer variant **25c'-y4** (QX3095; $C_{197}H_{343}N_{55}O_{51}S$; expected $[M+4H^+]/4 = 1082.900$ Da. Observed $[M+4H^+]/4 = 1082.906$ Da.




Figure S57. ESI-TOF spectrum for acidic monomer **24b-z4** (ND1095; $C_{187}H_{297}N_{51}O_{70}S$; expected $[M+4H^+]/4 = 1103.282$ Da). Observed $[M+4H^+]/4 = 1103.277$ Da.




Figure S58. ESI-TOF spectrum for disulfide-bound coiled-coil variant **d24b/25c'-z4y4** (QX3096; $C_{384}H_{638}N_{106}O_{121}S_2$; expected $[M+8H^+]/8 = 1092.839$ Da). Observed $[M+8H^+]/8 = 1093.064$ Da.




Figure S59. ESI-TOF spectrum for stapled disulfide-bound coiled-coil variant **sd24b/25c'-z4y4** (QX3096s; $C_{384}H_{638}N_{106}O_{121}S_2$; expected $[M+8H^+]/8 = 1092.839$ Da). Observed $[M+8H^+]/8 = 1093.072$ Da.




Figure S60. ESI-TOF MS data for (A) disulfide-bound coiled-coil variant **d24b/25c'-z4y4** before (QX3096; C₃₈₄H₆₃₈N₁₀₆O₁₂₁S₂; expected [M+8H⁺]/8 = 1092.839 Da) and (B,C) after exposure to reducing conditions (1M DTT) for at least 8h. Following reduction, **d24b/25c'-z4y4** splits into its component peptides: **24b-z4** (QX3095; C₁₉₇H₃₄₃N₅₅O₅₁S; expected mass [M+4H⁺]/4 = 1082.900 Da) and **25c'-y4** (ND1095; C₁₈₇H₂₉₇N₅₁O₇₀S; expected mass [M+4H⁺]/4 = 1103.282 Da). Also shown are ESI-TOF MS data for (D) triazole-stapled disulfide-bound coiled-coil variant **sd24b/25c'-z4y4** before (QX3096s; C₃₈₄H₆₃₈N₁₀₆O₁₂₁S₂; expected [M+8H⁺]/8 = 1092.839 Da) and (E,F) after exposure to reducing conditions (1M DTT) for at least 8h (C₃₈₄H₆₄₀N₁₀₆O₁₂₁S₂; expected [M+8H⁺]/8 = 1093.091 Da after reduction of disulfide bond to free cysteine residues). Note that **sd24b/25c'-z4y4** remains intact even after disulfide reduction due to the triazole staple.




Figure S61. ESI-TOF spectrum for acidic monomer **7f-z4** (QX22951; $C_{187}H_{297}N_{51}O_{70}S$; expected $[M+4H^+]/4 = 1103.282$ Da). Observed $[M+4H^+]/4 = 1103.298$ Da.




Figure S62. ESI-TOF spectrum for basic monomer **10b'-x** (QX22952; $C_{188}H_{329}N_{57}O_{44}S$; expected $[M+4H^+]/4 = 1031.383$ Da). Observed $[M+4H^+]/4 = 1031.397$ Da.




Figure S63. ESI-TOF spectrum for disulfide-bound coiled-coil **d7f/10b'-z4x** (QX2295; $C_{375}H_{624}N_{108}O_{114}S_2$; expected $[M+8H^+]/8 = 1067.081$ Da). Observed $[M+8H^+]/8 = 1067.088$ Da.




Figure S64. ESI-TOF spectrum for stapled disulfide-bound coiled-coil variant **sd7f/10b'-z4x** (QX2295s; $C_{375}H_{624}N_{108}O_{114}S_2$; expected $[M+6H^+]/6 = 1422.438$ Da). Observed $[M+6H^+]/6 = 1422.428$ Da.




Figure S65. ESI-TOF MS data for (A) disulfide-bound coiled-coil variant **d7f10b'-z4x** before (QX2295; C₃₇₅H₆₂₄N₁₀₈O₁₁₄S₂; expected $[M+8H^+]_8 = 1067.081$ Da) and (B,C) after exposure to reducing conditions (1M DTT) for at least 8h. Following reduction, **d7f10b'-z4x** splits into its component peptides: **7f-z4** (QX22951; C₁₈₈H₂₉₇N₅₁O₇₀S; expected mass $[M+4H^+]_4 = 1103.282$) and **10b'-x** (QX22952; C₁₈₈H₃₂₉N₅₇O₄₄S; expected mass $[M+4H^+]_4 = 1031.383$ Da). Also shown are ESI-TOF MS data for (D) triazole-stapled disulfide-bound coiled-coil variant **sd7f10b'-z4x** before (QX2295s; C₃₇₅H₆₂₄N₁₀₈O₁₁₄S₂; expected $[M+7H^+]_7 = 1219.377$ Da) and (E,F) after exposure to reducing conditions (1M DTT) for at least 8h (C₃₇₅H₆₂₆N₁₀₈O₁₁₄S₂; expected $[M+7H^+]_7 = 1219.665$ Da after reduction of disulfide bond to free cysteine residues). Note that **sd7f10b'-z4x** remains intact even after disulfide reduction due to the triazole staple.




Figure S66. ESI-TOF spectrum for coiled-coil variant **7f-z4** (QX30984; $C_{187}H_{297}N_{51}O_{70}S$; expected $[M+4H^+]/4 = 1103.282$ Da). Observed $[M+4H^+]/4 = 1103.282$ Da.




Figure S67. ESI-TOF spectrum for coiled-coil variant **10b'-y4** (QX30982; $C_{198}H_{348}N_{58}O_{49}S$; expected $[M+4H^+]/4 = 1089.664$ Da). Observed $[M+4H^+]/4 = 1089.671$ Da.




Figure S68. ESI-TOF spectrum for coiled-coil variant **d7f/10b'-z4y4** (QX3101; $C_{385}H_{643}N_{109}O_{119}S_2$; expected $[M+8H^+]/8 = 1096.221$ Da). Observed $[M+8H^+]/8 = 1096.447$ Da.




Figure S69. ESI-TOF spectrum for coiled-coil variant **sd7f/10b'-z4y4** (QX3101s; $C_{385}H_{643}N_{109}O_{119}S_2$; expected $[M+7H^+]/7 = 1252.680$ Da). Observed $[M+8H^+]/8 = 1253.046$ Da.









Figure S70. ESI-TOF MS data for (A) disulfide-bound coiled-coil variant **d7f10b'-z4y4** before (QX3101; $C_{385}H_{643}N_{109}O_{119}S_2$; expected $[M+8H^+]_8 = 1096.221$ Da) and (B,C) after exposure to reducing conditions (1M DTT) for at least 8h. Following reduction, **d7f10b'-z4y4** splits into its component peptides: **7f-z4** (QX30984; $C_{187}H_{297}N_{51}O_{70}S$; expected mass $[M+4H^+]_4 = 1103.282$ Da) and **10b'-y4** (QX30982; $C_{198}H_{348}N_{58}O_{49}S$; expected mass $[M+4H^+]_4 = 1089.664$ Da). Also shown are ESI-TOF MS data for (D) triazole-stapled disulfide-bound coiled-coil variant **sd7f10b'-z4y4** before (QX3101s; $C_{385}H_{643}N_{109}O_{119}S_2$; expected $[M+8H^+]_8 = 1096.221$ Da) and (E,F) after exposure to reducing conditions (1M DTT) for at least 8h ($C_{385}H_{645}N_{109}O_{119}S_2$; expected $[M+8H^+]_8 = 1096.473$ Da after reduction of disulfide bond to free cysteine residues). Note that **sd7f10b'-z4y4** remains intact even after disulfide reduction due to the triazole staple.




Figure S71. ESI-TOF spectrum for acidic monomer **27e-x** (QX22711; $C_{178}H_{279}N_{47}O_{64}S$; expected $[M+4H^+]/4 = 1033.752$ Da). Observed $[M+4H^+]/4 = 1033.757$ Da.




Figure S72. ESI-TOF spectrum for basic monomer **29g'-x** (QX22712; $C_{187}H_{324}N_{56}O_{46}S$; expected $[M+4H^+]/4 = 1031.620$ Da). Observed $[M+4H^+]/4 = 1031.624$ Da.




Figure S73. ESI-TOF spectrum for disulfide-bound coiled-coil variant **d27e/29g'-xx** (QX2271; $C_{365}H_{601}N_{103}O_{110}S_2$; expected $[M+8H^+]/8 = 1032.434$ Da). Observed $[M+8H^+]/8 = 1032.442$ Da.







Figure S74. ESI-TOF spectrum for stapled disulfide-bound coiled-coil variant **sd27e/29g'-x4x** (QX2283; $C_{373}H_{617}N_{109}O_{113}S_2$; expected $[M+8H^+]/8 = 1062.950$ Da). Observed $[M+8H^+]/8 = 1062.952$ Da.




A




B




C



D



E



F

Figure S75. ESI-TOF MS data for (A) disulfide-bound coiled-coil variant **d27e/29g'-xx** before (QX2271; $C_{365}H_{601}N_{103}O_{110}S_2$; expected $[M+8H]^+/8 = 1032.434$ Da) and (B,C) after exposure to reducing conditions (1M DTT) for at least 8h. Following reduction, **d27e/29g'-xx** splits into its component peptides: **27e-x** (QX22711; $C_{178}H_{279}N_{47}O_{64}S$; expected mass $[M+4H]^+/4 = 1033.752$) and **29g'-x** (QX22712; $C_{187}H_{324}N_{56}O_{46}S$; expected mass $[M+4H]^+/4 = 1031.620$ Da). However, neither of these appear in (B,C). Instead, we observe a peak with $m/z = 1108.6277$ Da and isotopic spacing consistent with $z = 4$. This peak is consistent with bis-DTT adduct of **29g'-x** ($C_{195}H_{344}N_{56}O_{50}S_5$; expected $[M+4H]^+/4 = 1108.626$), which could be formed via tandem thiol-yne and thiol-ene reactions between the propargylglycine of **29g'-x** and two equivalents of DTT. Peptide **27e-x** does not appear in (B,C) for reasons that are unclear. Also shown are ESI-TOF MS data for (D) triazole-stapled disulfide-bound coiled-coil variant **sd27e/29g'-x4x** before (QX2283; $C_{373}H_{617}N_{109}O_{113}S_2$; expected $[M+8H]^+/8 = 1062.950$ Da) and (E,F) after exposure to reducing conditions (1M DTT) for at least 8h ($C_{373}H_{619}N_{109}O_{113}S_2$; expected $[M+8H]^+/8 = 1063.202$ Da after reduction of disulfide bond to free cysteine residues). Note that **sd27e/29g'-x4x** remains intact even after disulfide reduction due to the triazole staple.




Figure S76. ESI-TOF spectrum for stapled disulfide-bound coiled-coil variant **sd27e/29g'-x4px** (QX3079; $C_{383}H_{636}N_{110}O_{118}S_2$; expected $[M+8H^+]/8 = 1092.090$ Da). Observed $[M+8H^+]/8 = 1092.075$ Da.





Figure S77. ESI-TOF MS data for (A) bis-triazole-stapled disulfide-bound coiled-coil variant **sd27e/29g'-x4px** (QX3079; $C_{383}H_{636}N_{110}O_{118}S_2$; expected $[M+8H^+]/8 = 1092.090$ Da) and (B) after exposure to reducing conditions (1M DTT) for at least 8h ($C_{383}H_{638}N_{110}O_{118}S_2$; expected $[M+8H^+]/8 = 1092.342$ Da after reduction of disulfide bond to free cysteine residues). Note that **sd27e/29g'-x4px** remains intact even after disulfide reduction due to the bis-triazole staple.




Figure S78. ESI-TOF spectrum for acidic monomer (***R***)-**27e-x** (ZJ10551; $C_{178}H_{279}N_{47}O_{64}S$; expected $[M+8H^+]/8 = 1033.752$ Da). Observed $[M+8H^+]/8 = 1033.751$ Da.




Figure S79. ESI-TOF spectrum for disulfide-bound coiled-coil variant (***R,S***)-**d27e/29g'-xx** (QX3118; $C_{365}H_{601}N_{103}O_{110}S_2$; expected $[M+8H^+]/8 = 1032.434$ Da). Observed $[M+8H^+]/8 = 1033.541$ Da.




Figure S80. ESI-TOF spectrum for stapled disulfide-bound coiled-coil variant (***R,S***)-**sd27e/29g'-x4x** (ZJ1056; $C_{373}H_{617}N_{109}O_{113}S_2$; expected $[M+8H^+]/8 = 1062.950$ Da). Observed $[M+8H^+]/8 = 1063.073$ Da.




Figure S81. ESI-TOF MS data for (A) disulfide-bound coiled-coil variant *(R,S)*-d27e/29g'-xx before (QX3118; C₃₆₅H₆₀₁N₁₀₃O₁₁₀S₂; expected [M+8H⁺]/8 = 1032.434 Da) and (B,C) after exposure to reducing conditions (1M DTT) for at least 8h. Following reduction, *(R,S)*-d27e/29g'-xx splits into its component peptides: *(R)*-27e-x (ZJ10551; C₁₇₈H₂₇₉N₄₇O₆₄S; expected mass [M+4H⁺]/4 = 1033.752) and 29g'-x (QX22712; C₁₈₇H₃₂₄N₅₆O₄₆S; expected mass [M+4H⁺]/4 = 1031.620 Da). Also shown are ESI-TOF MS data for (D) triazole-stapled disulfide-bound coiled-coil variant *(R,S)*-sd27e/29g'-x4x before (ZJ1056; C₃₇₃H₆₁₇N₁₀₉O₁₁₃S₂; expected [M+8H⁺]/8 = 1062.950 Da) and (E,F) after exposure to reducing conditions (1M DTT) for at least 8h (C₃₇₃H₆₁₉N₁₀₉O₁₁₃S₂; expected [M+8H⁺]/8 = 1063.202 Da after reduction of disulfide bond to free cysteine residues). Note that *(R,S)*-sd27e/29g'-x4x remains intact even after disulfide reduction due to the triazole staple.




Figure S82. ESI-TOF MS spectrum for affibody **a** (CD1054). Expected $[M+5H^+]/5 = 1341.102$ Da. Observed $[M+5H^+]/5 = 1341.106$ Da.




Figure S83. ESI-TOF MS spectrum for affibody variant **a8/42-xx** (QX3102). Expected $[M+5H^+]/5 = 1339.102$ Da. Observed $[M+5H^+]/5 = 1339.123$ Da.




Figure S84. ESI-TOF MS spectrum for affibody variant **sa8/42-x4x** (QX3106). Expected $[M+5H^+]/5 = 1387.927$ Da. Observed $[M+5H^+]/5 = 1387.915$ Da.




Figure S85. ESI-TOF MS spectrum for fluorescent affibody variant **fa** (ZJ10611). Expected $[M+5H^+]/5 = 1412.914$ Da. Observed $[M+5H^+]/5 = 1412.883$ Da.




Figure S86. ESI-TOF MS spectrum for fluorescent affibody variant **fa8/42-xx** (ZJ10612). Expected $[M+5H^+]/5 = 1410.913$ Da. Observed $[M+5H^+]/5 = 1410.888$ Da.




Figure S87. ESI-TOF MS spectrum for fluorescent affibody variant **fsa8/42-x4x** (ZJ1062). Expected $[M+5H^+]/5 = 1459.738$ Da. Observed $[M+5H^+]/5 = 1459.705$ Da.

4. Analytical HPLC data




Figure S88. Analytical HPLC Data for variant **d20e/22g'-z4x** (ZJ10511). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S89. Analytical HPLC Data for variant **sd20e/22g'-z4x** (ZJ10511s). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S90. Analytical HPLC Data for variant **d27e/29g'-xx** (QX2271). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S91. Analytical HPLC Data for variant **d13e/15g'-z4x** (QX31171). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S852. Analytical HPLC Data for variant **sd13e/15g'-z4x** (QX31171s). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S93. Analytical HPLC Data for variant **d6e/8g'-z4x** (QX2292). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S94. Analytical HPLC Data for variant **sd6e/8g'-z4x** (QX2292s). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S95. Analytical HPLC Data for variant **d27e/22g'-z4x** (QX2294). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S96. Analytical HPLC Data for variant **sd27e/22g'-z4x** (QX2294s). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S97. Analytical HPLC Data for variant **d6e/1g'-z4x** (QX31172). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S98. Analytical HPLC Data for variant **sd6e/1g'-z4x** (QX31172s). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S99. Analytical HPLC Data for variant **d27e/29g'-z2x** (QX2289). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S100. Analytical HPLC Data for variant **sd27e/29g'-z2x** (QX2289s). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S101. Analytical HPLC Data for variant **d27e/22g'-z2x** (QX2293). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S102. Analytical HPLC Data for variant **sd27e/22g'-z2x** (QX2293s). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S103. Analytical HPLC Data for variant **d24b/25c'-z4x** (QX2291). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S104. Analytical HPLC Data for variant **sd24b/25c'-z4x** (QX2291s). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S105. Analytical HPLC Data for variant **d24b/25c'-z4y4** (QX3096). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S106. Analytical HPLC Data for variant **sd24b/25c'-z4y4** (QX3096s). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S107. Analytical HPLC Data for variant **d7f/10b'-z4x** (QX2295). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S108. Analytical HPLC Data for variant **sd7f10b'-z4x** (QX2295). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S109. Analytical HPLC Data for variant **d7f10b'-z4y4** (QX3101). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S110. Analytical HPLC Data for variant **sd7f10b'-z4y4** (QX3101s). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S111. Analytical HPLC Data for coiled-coil variant **sd27e/29g'-x4x** (QX2283). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S112. Analytical HPLC Data for variant **sd27e/29e'-x4px** (QX3079). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S113. Analytical HPLC Data for native affibody **a** (CD1054). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S114. Analytical HPLC Data for affibody variant **a8/42-xx** (QX3102). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S115. Analytical HPLC Data for stapled affibody variant **sa8/42-x4x** (QX3106). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S116. Analytical HPLC Data for fluorescent affibody variant **fa** (ZJ10611). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S117. Analytical HPLC Data for fluorescent affibody variant **fa8/42-xx** (ZJ10612). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.




Figure S118. Analytical HPLC Data for fluorescent native affibody variant **fa8/42-x4x** (ZJ1062). Protein solution was injected onto a C18 analytical column and eluted using a linear gradient of 10-60% B (A = H₂O, 0.1% TFA; B = MeCN, 0.1% TFA) over 50 minutes, followed by a 10-minute rinse (95% B), and a 10-minute column re-equilibration.

5. Global Fitting of Variable Temperature CD Data

The conformational stability of stapled variants and their non-stapled counterparts was assessed by variable-temperature circular dichroism spectropolarimetry. Data from three replicate variable temperature CD experiments were each fit globally to a model for a two-state thermally induced unfolding transition using the program Mathematica (Wolfram Research). We used a model based on two-state monomer folding/unfolding equilibrium for stapled coiled-coil variants **sd20e/22g'-z4x**, **sd13e/15g'-z4x**, **sd6e/8g'-z4x**, **sd27e/22g'-z4x**, **sd6e/1g'-z4x**, **sd27e/29g'-z2x**, **sd27e/22g'-z2x**, **sd24b/25c'-z4x**, **sd24b/25c'-z4y4**, **sd7f/10b'-z4x**, **sd7f/10b'-z4y4**, **sd27e/29g'-x4x**, **sd27e/29g'-x4px**, and **(R,S)-sd27e/29g'-x4x**; for their non-stapled counterparts variants **d20e/22g'-z4x**, **d13e/15g'-z4x**, **d6e/8g'-z4x**, **d27e/22g'-z4x**, **d6e/1g'-z4x**, **d27e/29g'-z2x**, **d27e/22g'-z2x**, **d24b/25c'-z4x**, **d24b/25c'-z4y4**, **d7f/10b'-z4x**, **d7f/10b'-z4y4**, **d27e/29g'-xx**, and **(R,S)-d27e/29g'-xx**; for stapled HER2 affibody **sa8/42-xx**; for its non-stapled counterpart **a8/42-x4x**; and for native HER2 affibody **a**. This model is described in equation S1:

$$[\theta] = \frac{[K \cdot (a_n + b_n \cdot T) + (c_n + d_n \cdot T)]}{1 + K}, \quad (S1)$$

where T is temperature in Kelvin, a_n is the y-intercept and b_n is the slope of the pre-transition baseline for melt n (a_1 and b_1 for replicate 1, a_2 and b_2 for replicate 2, a_3 and b_3 for replicate 3, etc.); c_n is the y-intercept and d_n is the slope of the post-transition baseline for replicate n (c_1 and d_1 for replicate 1, c_2 and d_2 for replicate 2, c_3 and d_3 for replicate 3, etc.); and K is the temperature-dependent folding equilibrium constant. K is related to the temperature-dependent free energy of folding ΔG according to the following equation:

$$K = \exp\left[-\frac{\Delta G}{RT}\right], \quad (S2)$$

where R is the universal gas constant (0.0019872 kcal/mol/K). ΔG is a function of temperature, as shown in the following equation:

$$\Delta G = \frac{\Delta H_0 \cdot (T_m - T)}{T_m} + \Delta C_p \cdot (T - T_m - T \cdot \ln\left[\frac{T}{T_m}\right]), \quad (S3)$$

where T_m is the midpoint of the unfolding transition and the temperature at which $\Delta G_f = 0$; ΔH_0 is the change in enthalpy upon folding at $T = T_m$; and ΔC_p is the change in heat capacity upon folding. In some cases, we found that some fit parameters had sufficiently high standard errors as to render them indistinguishable from zero and therefore not essential to the fit (as judged by their p-values). When this occurred, we repeated the fitting process without the non-essential parameters. We used the fit parameters for each variant to calculate the ΔG values given in the main text; we calculated the uncertainty for each ΔG value by propagation of error using the standard errors of the fit parameters.

Molar ellipticity data at 222 nm ($[\theta]_{222}$), melting temperatures (T_m), and folding free energies ΔG for variants **d27e/29g'-z4x** and **sd27e/29g'-z4x**; **d27e/22g'-z4x** and **sd27e/22g'-z4x**; **d24b/25c'-z4x** and **sd24b/25c'-z4x**; **d20e/22g'-z4x** and **sd20e/22g'-z4x**; **d13e/15g'-z4x** and **sd13e/15g'-z4x**; **d6e/8g'-z4x** and **sd6e/8g'-z4x**; **d6e/1g'-z4x** and **sd6e/1g'-z4x**; **d27e/29g'-z2x** and **sd27e/29g'-z2x**; **d27e/22g'-z2x** and **sd27e/22g'-z2x**; **d24b/25c'-z4y4** and **sd24b/25c'-z4y4**; **d7f/10b'-z4x** and **sd7f/10b'-z4x**; **d7f/10b'-z4y4** and **sd7f/10b'-z4y4**; **d27e/29g'-xx**, **sd27e/29g'-x4x**, and **sd27e/29g'-x4px**; and HER2 affibody variants **a**, **a8/42-xx** and **sa8/42-x4x** are given in Table S2. $[\theta]_{222}$ is a well-known indicator of α -helical secondary structure, whereas T_m values are indicators of tertiary/quaternary structural stability. Values of the ratio $[\theta]_{222}/[\theta]_{208}$ near 1.1 are also considered diagnostic of coiled-coil tertiary/quaternary structures. However, we were not able to measure $[\theta]_{208}$ due to the excessively high dynode values we observed at wavelengths less than 210 nm in solutions of these variants in 20 mM phosphate buffer (pH 7) + 4 M guanidinium chloride (which was necessary to observe complete or nearly complete thermal unfolding transitions). Therefore, our assessment of coiled-coil tertiary structural stability must rely on T_m values alone.

$[\theta]_{222}$ values for these variants are consistent with α -helical secondary structure and T_m values are consistent with coiled-coil tertiary structure. However, the magnitude of $[\theta]_{222}$ varies widely from variant to variant and is not well correlated with T_m (Figure S113). Increases in T_m associated with PEG stapling are sometimes associated with increases in $[\theta]_{222}$ (compare variants **d27e/29g'-z4x** vs. **sd27e/29g'-z4x**; **d20e/22g'-z4x** vs. **sd20e/22g'-z4x**; **d13e/15g'-z4x** vs. **sd13e/15g'-z4x**; **d27e/22g'-z4x** vs. **sd27e/22g'-z4x**; **d6e/1g'-z4x** vs. **sd6e/1g'-z4x**; **d7f/10b'-z4y4** vs. **sd7f/10b'-z4y4**; **d27e/22g'-z4x** vs. **sd27e/22g'-z4x**; and **d27e/29g'-xx** vs. **sd27e/29g'-x4x**), but not always (compare variants **d6e/8g'-z4x** vs. **sd6e/8g'-z4x**; **d7f/10b'-z4x** vs. **sd7f/10b'-z4x**; **sd27e/29g'-x4px** vs. **sd27e/29g'-x4x**; and **a8/42-xx** vs. **sa8/42-x4x**). This observation is interesting because it is generally accepted that α -helical secondary structure forms concomitantly with coiled-coil association: that is, individual subunits are only α -helical within the coiled-coil assembly, not on their own. It is possible that the covalent linkages between helices in the disulfide-bound coiled-coil variants and their stapled counterparts attenuate the connection between secondary and tertiary structural stability. However, we previously³ observed a similar lack of correlation between $[\theta]_{222}$ and T_m values in a study of non-stapled non-disulfide-bound trimeric α -helical coiled coils. Despite this anomaly, crystallography confirmed that these previously characterized variants adopted their intended trimeric coiled-coil quaternary structures. Therefore, we believe that the lack of correlation we observed here between $[\theta]_{222}$ and T_m , while interesting, does not substantially change the conclusions

described in the main text.

CD spectra and variable temperature CD data for each variant are shown in Figures S114–S143, along with the fit parameters \pm standard error. Standard parameter errors were used to estimate the uncertainty in the thermodynamic values given in the main text by propagation of error.

Table S2. Molar ellipticity, melting temperatures and folding free energies for non-stapled variants and their PEG-stapled counterparts.^a

Protein	Distance between staple positions (Å)	Calculated Staple Length (Å)	[θ] ₂₂₂ (deg cm ² dmol ⁻¹ x 10 ³)	T _m (°C)	Impact of Stapling		
					$\Delta\Delta G$ (kcal/mol)	$\Delta\Delta H$ (kcal/mol)	$-\Delta\Delta S$ (kcal/mol)
d27e/29g'-z4x			-24.6	41.1 ± 0.2			
sd27e/29g'-z4x	9.2	18.5	-34.5	48.2 ± 0.1	-0.65 ± 0.02	1.3 ± 0.6	-1.9 ± 0.6
d20e/22g'-z4x			-24.0	41.8 ± 0.2			
sd20e/22g'-z4x	9.2	18.5	-31.3	54.3 ± 0.1	-1.09 ± 0.02	1.6 ± 0.6	-2.7 ± 0.6
d13e/15g'-z4x			-28.2	42.4 ± 0.1			
sd13e/15g'-z4x	9.7	18.5	-29.7	57.7 ± 0.1	-1.33 ± 0.02	2.1 ± 0.5	-3.4 ± 0.5
d6e/8g'-z4x			-31.6	39.5 ± 0.2			
sd6e/8g'-z4x	10.6	18.5	-18.2	69.1 ± 0.1	-2.53 ± 0.04	-1.9 ± 0.6	-0.7 ± 0.6
d27e/22g'-z4x			-22.5	43.2 ± 0.1			
sd27e/22g'-z4x	6.3	18.5	-40.4	63.6 ± 0.1	-2.01 ± 0.02	-2.7 ± 0.5	0.6 ± 0.5
d6e/1g'-z4x			-24.7	45.0 ± 0.1			
sd6e/1g'-z4x	6.0	18.5	-27.6	73.7 ± 0.2	-2.30 ± 0.04	1.7 ± 0.6	-4.0 ± 0.6
d24b/25c'-z4x			-38.0	43.4 ± 0.1			
sd24b/25c'-z4x	14.3	18.5	-11.4	33.0 ± 0.2	0.65 ± 0.02	8.1 ± 0.5	-7.4 ± 0.5
d7f/10b'-z4x			-24.9	42.6 ± 0.2			
sd7f/10b'-z4x	15.6	18.5	-11.1	51.4 ± 0.3	-0.61 ± 0.03	8.8 ± 0.9	-9.4 ± 0.9
d24b/25c'-z4y4			-21.3	46.5 ± 0.1			
sd24b/25c'-z4y4	14.3	28.5	-16.5	44.5 ± 0.2	0.17 ± 0.02	0.8 ± 0.6	-0.6 ± 0.6
d7f/10b'-z4y4			-16.4	43.7 ± 0.2			
sd7f/10b'-z4y4	15.6	28.5	-30.2	54.2 ± 0.2	-0.68 ± 0.01	6.6 ± 0.6	-7.2 ± 0.6
d27e/29g'-z2x			-24.2	38.8 ± 0.2			
sd27e/29g'-z2x	9.2	8.1	-16.3	33.7 ± 0.1	0.31 ± 0.01	6.1 ± 0.4	-5.8 ± 0.4
d27e/22g'-z2x			-20.4	43.4 ± 0.1			
sd27e/22g'-z2x	6.3	8.1	-23.1	64.9 ± 0.3	-2.04 ± 0.03	-0.5 ± 0.6	-1.5 ± 0.6
d27e/29g'-xx			-22.4	39.8 ± 0.2			
sd27e/29g'-x4x	9.2	19.3	-52.2	52.9 ± 0.2	-1.08 ± 0.03	-2.0 ± 0.5	0.9 ± 0.5
sd27e/29g'-x4px			-28.1	53.4 ± 0.1	-1.21 ± 0.02	-4.1 ± 0.5	2.9 ± 0.5
affibody a			-7.0	66.4 ± 0.2			
a8/42-xx	7.4	19.3	-38.5	60.9 ± 0.1	0.64 ± 0.02	-2.1 ± 1.1	2.8 ± 1.1
sa8/42-x4x			-16.1	76.1 ± 0.1	-1.09 ± 0.03	3.5 ± 1.3	-4.6 ± 1.3

^aDistance between staple positions for each variant were calculated by measuring the distance between the centers of mass of the corresponding side chains in the crystal structure of the parent disulfide-bound coiled-coil heterodimer **dA/B** (PDB ID: 1KD9). Calculated staple length measured from β -carbon to β -carbon within model staple structures (see supporting information) optimized in Gaussian 16 using density functional theory APFD and the 6-31G+d,p basis set. $\Delta\Delta G$, $\Delta\Delta H$, and $-\Delta\Delta S$ values for each variant are given \pm std. error in kcal/mol at the melting temperature of its corresponding non-stapled counterpart at 15 μ M protein concentration in 20 mM sodium phosphate buffer (pH 7) + 4.0 M GdnHCl, except for affibody **a**, non-stapled **a8/42-xx**, and stapled **sa8/42-x4x**, which were characterized without denaturant.




Figure S119. Plot of $[\theta]_{222}$ vs. melting temperature for variants **d27e/29g'-z4x** and **sd27e/29g'-z4x**; **d27e/22g'-z4x** and **sd27e/22g'-z4x**; **d24b/25c'-z4x** and **sd24b/25c'-z4x**; **d20e/22g'-z4x** and **sd20e/22g'-z4x**; **d13e/15g'-z4x** and **sd13e/15g'-z4x**; **d6e/8g'-z4x** and **sd6e/8g'-z4x**; **d6e/1g'-z4x** and **sd6e/1g'-z4x**; **d27e/29g'-z2x** and **sd27e/29g'-z2x**; **d27e/22g'-z2x** and **sd27e/22g'-z2x**; **d24b/25c'-z4y4** and **sd24b/25c'-z4y4**; **d7f/10b'-z4x** and **sd7f/10b'-z4x**; **d7f/10b'-z4y4** and **sd7f/10b'-z4y4**; **d27e/29g'-xx**, **sd27e/29g'-x4x**, and **sd27e/29g'-x4px**; and HER2 affibody variants **a**, **a8/42-xx** and **sa8/42-x4x**.




Figure S120. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide-bound coiled-coil variant **d20e/22g'-z4x** (ZJ10511) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from eq. S1–S3 appear in the table, as do calculated values of ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S121. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM stapled disulfide-bound coiled-coil variant **sd20e/22g'-z4x** (ZJ10511s) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from eq. S1–S3 appear in the table, as do calculated values of ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S122. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide-bound coiled-coil variant **d13e/15g'-z4x** (QX31171) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from eq. S1–S3 appear in the table, as do calculated values of ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S123. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM stapled disulfide-bound coiled-coil variant **sd13e/15g'-z4x** (QX31171s) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from eq. S1–S3 appear in the table, as do calculated values of ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S124. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide-bound coiled-coil variant **d6e/8g'-z4x** (QX2292) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from eq. S1–S3 appear in the table, as do calculated values of ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S125. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM stapled disulfide-bound coiled-coil variant **sd6e/8g'-z4x** (QX2292s) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from eq. S1–S3 appear in the table, as do calculated values of ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S126. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide-bound coiled-coil variant **d27e/22g'-z4x** (QX2294) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from eq. S1–S3 appear in the table, as do calculated values of ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S127. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide-bound coiled-coil variant **sd27e/22g'-z2x** (QX2294s) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from eq. S1–S3 appear in the table, as do calculated values for ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S128. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide-bound coiled-coil variant **d6e/1g'-z4x** (QX31172) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from eq. S1–S3 appear in the table, as do calculated values of ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S129. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM stapled disulfide-bound coiled-coil variant **sd6e/1g'-z4x** (QX31172s) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from eq. S1–S3 appear in the table, as do calculated values of ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S130. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide-bound coiled-coil variant **d27e/29g'-z2x** (QX2289) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔG_f , ΔH_f , and $-T\Delta S_f$ at \pm standard error at the indicated temperature.




Figure S131. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM stapled disulfide-bound coiled-coil variant **sd27e/29g'-z2x** (QX2289s) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔG_f , ΔH_f , and $-T\Delta S_f$ at \pm standard errors at the indicated temperature.




Figure S132. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide-bound coiled-coil variant **d27e/22g'-z4x** (QX2293) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S133. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM stapled disulfide-bound coiled-coil variant **sd27e/22g'-z4x** (QX2293s) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S134. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide-bound coiled-coil variant **d24b/25c'-z4x** (QX2291) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from eq. S1–S3 appear in the table, as do calculated values for ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S135. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM stapled disulfide-bound coiled-coil variant **sd24b/25c'-z4x** (QX2291s) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from eq. S1–S3 appear in the table, as do calculated values for ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S136. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide-bound coiled-coil variant **d24b/25c'-z4y4** (QX3096) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S137. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM stapled disulfide-bound coiled-coil variant **sd24b/24c'-z4y4** (QX3096s) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S138. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM stapled disulfide-bound coiled-coil variant **d7f/10b'-z4x** (QX2295) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S139. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM stapled disulfide-bound coiled-coil variant **sd7f/10b'-z4x** (QX2295s) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S86. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide-bound coiled-coil variant **d7f/10b'-z4y4** (QX3101) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure 141. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM stapled disulfide-bound coiled-coil variant **sd7f/10b'-z4y4** (QX3101s) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S142. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM disulfide-bound coiled-coil variant **d27e/29g'-xx** (QX2271) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S143. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM stapled disulfide-bound coiled-coil variant **sd27e/29g'-x4x** (QX2283) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S144. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM branched PEG-stapled disulfide-bound coiled-coil variant **sd27e/29g'-x4px** (QX3079) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S145. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM stapled disulfide-bound coiled-coil variant **(R,S)-d27e/29g'-xx** (QX3118) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S146. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM stapled disulfide-bound coiled-coil variant (R,S)-sd27e/29g'-xx (QX3118) in 20 mM sodium phosphate (pH 7) with 4 M GdnHCl. Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S147. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM HER2 native affibody variant a (CD1054) in 20 mM sodium phosphate (pH 7). Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S148. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM stapled affibody variant **a8/42-xx** (QX3102) in 20 mM sodium phosphate (pH 7). Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.




Figure S149. (A) CD spectra and (B–D) variable temperature CD data (triplicate) for 15 μM stapled affibody variant **sa8/42-x4x** (QX3106s) in 20 mM sodium phosphate (pH 7). Fit parameters from equations S1–S3 appear in the table, as do calculated values for ΔG_f , ΔH_f , and $-T\Delta S_f \pm$ standard error at the indicated temperature.

6. Proteolysis of coiled-coil variants

15 μM protein solutions in 20 mM sodium phosphate buffer (pH 7) were incubated at ambient temperature with 17 $\mu\text{g}/\text{mL}$ proteinase K respectively for up to 5 hours. At each of the several time points, the proteolysis reaction was quenched by adding 40 μL of aqueous trifluoroacetic acid (1% v/v) to 40 μL of the reaction mixture. The quenched mixture was then analyzed in triplicate by reverse phase HPLC analytical column, monitored by a UV-Vis detector at 220 nm. The degradation of the proteins was assessed using the integrated HPLC peak area to account for how much of the full-length protein remained at each time point. The protein half-lives were calculated by fitting the integrated peak areas as a function of time to a mono exponential decay equation:

$$\text{Area}(t) = A \cdot \exp [-kt],$$

where t is time in minutes, A is a constant corresponding to relative integrated peak area at $t = 0$, and τ is the decay time, which is related to the protein half-life $t_{1/2}$ ($t_{1/2} = \tau \ln 2$). Decay traces for proteins coiled-coil variants, **d27e/29g'-xx** (QX2271); **sd27e/29g'-x4x** (QX2283); **d27e/29g'-z2x** (QX2289); **sd27e/29g'-z2x** (QX2289s); **d24b/25c'-z4x** (QX2291); **sd24b/25c'-z4x** (QX2291s); **d6e/8g'-z4x** (QX2292); **sd6e/8g'-z4x** (QX2292s); **d27e/22g'-z2x** (QX2293); **sd27e/22g'-z2x** (QX2292s); **d27e/22g'-z4x** (QX2294); **sd27e/22g'-z4x** (QX2294s) are shown in Figures S142–S156.




Figure S150. Proteolysis of **d27e/29g'-xx** (QX2271) at 50 μM protein concentration in 20 mM sodium phosphate buffer pH 7 by proteinase K (17 $\mu\text{g}/\text{mL}$) as monitored by HPLC. Data points are shown as blue circles; each represents the average of three replicate experiments, with error bars representing standard error. The dashed line represents fit of the data to a mono exponential decay function, which was used to calculate the indicated apparent proteolysis rate constant.




Figure S151. Proteolysis of **sd27e/29g'-x4x** (QX2283) at 50 μM protein concentration in 20 mM sodium phosphate buffer pH 7 by proteinase K (17 $\mu\text{g}/\text{mL}$) as monitored by HPLC. Data points are shown as blue circles; each represents the average of three replicate experiments, with error bars representing standard error. The dashed line represents fit of the data to a mono exponential decay function, which was used to calculate the indicated apparent proteolysis rate constant.




Figure S152. Proteolysis of **d27e/29g¹-z2x** (QX2289) at 50 μ M protein concentration in 20 mM sodium phosphate buffer pH 7 by proteinase K (17 μ g/mL) as monitored by HPLC. Data points are shown as blue circles; each represents the average of three replicate experiments, with error bars representing standard error. The dashed line represents fit of the data to a mono exponential decay function, which was used to calculate the indicated apparent proteolysis rate constant.




Figure S153. Proteolysis of **sd27e/29g¹-z2x** (QX2289s) at 50 μ M protein concentration in 20 mM sodium phosphate buffer pH 7 by proteinase K (17 μ g/mL) as monitored by HPLC. Data points are shown as blue circles; each represents the average of three replicate experiments, with error bars representing standard error. The dashed line represents fit of the data to a mono exponential decay function, which was used to calculate the indicated apparent proteolysis rate constant.




Figure S154. Proteolysis of **d24b/25c¹-z4x** (QX2291) at 50 μ M protein concentration in 20 mM sodium phosphate buffer pH 7 by proteinase K (17 μ g/mL) as monitored by HPLC. Data points for are shown as blue circles; each represents the average of three replicate experiments, with error bars representing standard error. The dashed line represents fit of the data to a mono exponential decay function, which was used to calculate the indicated apparent proteolysis rate constant.




Figure S155. Proteolysis of **sd24b/25c'-z4x** (QX2291s) at 50 μ M protein concentration in 20 mM sodium phosphate buffer pH 7 by proteinase K (17 μ g/mL) as monitored by HPLC. Data points are shown as blue circles; each represents the average of three replicate experiments, with error bars representing standard error. The dashed line represents fit of the data to a mono exponential decay function, which was used to calculate the indicated apparent proteolysis rate constant.




Figure S156. Proteolysis of **d6e/8g'-z4x** (QX2292) at 50 μ M protein concentration in 20 mM sodium phosphate buffer pH 7 by proteinase K (17 μ g/mL) as monitored by HPLC. Data points are shown as blue circles; each represents the average of three replicate experiments, with error bars representing standard error. The dashed line represents fit of the data to a mono exponential decay function, which was used to calculate the indicated apparent proteolysis rate constant.




Figure S157. Proteolysis of **sd6e/8g'-z4x** (QX2292s) at 50 μ M protein concentration in 20 mM sodium phosphate buffer pH 7 by proteinase K (17 μ g/mL) as monitored by HPLC. Data points are shown as blue circles; each represents the average of three replicate experiments, with error bars representing standard error. The dashed line represents fit of the data to a mono exponential decay function, which was used to calculate the indicated apparent proteolysis rate constant.




Figure S158. Proteolysis of **d27e/22g'-z2x** (QX2293) at 50 μ M protein concentration in 20 mM sodium phosphate buffer pH 7 by proteinase K (17 μ g/mL) as monitored by HPLC. Data points are shown as blue circles; each represents the average of three replicate experiments, with error bars representing standard error. The dashed line represents fit of the data to a mono exponential decay function, which was used to calculate the indicated apparent proteolysis rate constant.




Figure S159. Proteolysis of **sd27e/22g'-z2x** (QX2293s) at 50 μ M protein concentration in 20 mM sodium phosphate buffer pH 7 by proteinase K (17 μ g/mL) as monitored by HPLC. Data points are shown as blue circles; each represents the average of three replicate experiments, with error bars representing standard error. The dashed line represents fit of the data to a mono exponential decay function, which was used to calculate the indicated apparent proteolysis rate constant.




Figure S160. Proteolysis of **d27e/22g'-z4x** (QX2294) at 50 μ M protein concentration in 20 mM sodium phosphate buffer pH 7 by proteinase K (17 μ g/mL) as monitored by HPLC. Data points are shown as blue circles; each represents the average of three replicate experiments, with error bars representing standard error. The dashed line represents fit of the data to a mono exponential decay function, which was used to calculate the indicated apparent proteolysis rate constant.




Figure S161. Proteolysis of **sd27e/22g³-z4x** (QX2294s) at 50 μM protein concentration in 20 mM sodium phosphate buffer pH 7 by proteinase K (17 $\mu\text{g}/\text{mL}$) as monitored by HPLC. Data points are shown as blue circles; each represents the average of three replicate experiments, with error bars representing standard error. The dashed line represents fit of the data to a mono exponential decay function, which was used to calculate the indicated apparent proteolysis rate constant.




Figure S162. Proteolysis of native HER2 affibody **a** (CD1054) at 15 μM protein concentration in 20 mM sodium phosphate buffer pH 7 by proteinase K (17 $\mu\text{g}/\text{mL}$) as monitored by HPLC. Data points are shown as green circles; each represents the average of three replicate experiments, with error bars representing standard error. The dashed line represents fit of the data to a mono exponential decay function, which was used to calculate the indicated apparent proteolysis rate constant.




Figure S163. Proteolysis of **a8/42-xx** (QX3102) at 15 μM protein concentration in 20 mM sodium phosphate buffer pH 7 by proteinase K (17 $\mu\text{g}/\text{mL}$) as monitored by HPLC. Data points are shown as blue circles; each represents the average of three replicate experiments, with error bars representing standard error. The dashed line represents fit of the data to a mono exponential decay function, which was used to calculate the indicated apparent proteolysis rate constant.




Figure S164. Proteolysis of **sa8/42-x4x** (QX3106) at 15 μM protein concentration in 20 mM sodium phosphate buffer pH 7 by proteinase K (17 $\mu\text{g}/\text{mL}$) as monitored by HPLC. Data points are shown as dark magenta circles; each represents the average of three replicate experiments, with error bars representing standard error. The dashed line represents fit of the data to a mono exponential decay function, which was used to calculate the indicated apparent proteolysis rate constant.

7. Fluorescence polarization binding assay

Fluorescent affibody solutions of peptides **fa** (ZJ10611), **fa8/42-xx** (ZJ10612), and **fa8/42-x4x** (ZJ1062), with concentrations of 247 μM , 263 μM , and 57 μM , respectively, were diluted with phosphate buffer (pH 7.4) to 100 nM. The His-tagged recombinant HER2/ERBB2 extracellular domain (hereafter called the HER2 protein) was obtained from SinoBiological and prepared at a concentration of 2.7 μM . We performed direct binding fluorescence polarization assays using a constant concentration of fluorescent affibody against varying concentrations of the recombinant HER2 extra-cellular domain. We prepared the fluorescent affibody solution in a glass tube with 4970 μL of PBS solution, 25 μL β -casein blocking agent (final concentration 0.1 mg/mL) and 5 μL of fluorescent affibody stock solution (100 nM), yielding a final affibody concentration of 100 pM. The glass tube containing the fluorescent affibody stock solution was inverted several times gently to mix. We aliquoted 200 μL of fluorescent affibody solution into each well of a 96-well plate and then added varying concentrations of the HER2 protein via serial dilution as follows: To the first well of the dilution series, we added an additional 190 μL of fluorescent affibody solution along with 10 μL of a 2.7 μM solution of the HER2 protein, bringing the total volume in the first well to 400 μL , such that the concentration of the HER2 protein in the first well was 65 nM. We then transferred 200 μL of the solution from the first well into the second well, leading to a two-fold dilution of the HER2 protein. We continued this dilution series by transferring 200 μL from well to well to generate a total of 19 different concentrations of HER2 protein, with the lowest concentration at 0.124 pM. Three 60 μL aliquots from each well were then transferred to a 384-well plate. We allowed 30 minutes for equilibration and measured the fluorescence polarization in each well using a Biotek Synergy Neo microplate reader with fluorescent polarization filters #4 (Dual FP) and #65 (FP 485/530, FP 530/590). We averaged the fluorescence polarization for these three replicate wells at each concentration of HER2 protein. We repeated this experiment for each affibody variant a total of three times on separate occasions. Data for **fa** (ZJ10611), **fa8/42-xx** (ZJ10612), and **fa8/42-x4x** (ZJ1062) are shown in Figures S165-167. The data for the native variant **fa** were too noisy to justify further analysis. However, we fit the data for variant **fa8/42-xx** and its stapled counterpart **fa8/42-x4x** to the following equation:

$$P = \frac{B_n \cdot [\text{affibody}]}{K_d + [\text{affibody}]}, \quad (\text{S4})$$

where P is fluorescence polarization, [affibody] is the concentration of fluorescent affibody in M; B_n is the maximum fluorescence polarization (B_1 for replicate 1; B_2 for replicate 2; B_3 for replicate 3); K_d is the dissociation constant in M for binding of the fluorescent affibody to the HER2 protein. K_d values, fit parameters, and statistics appear in Figure S166–S167.




Figure S165. Fluorescence polarization data of native fluorescent affibody **fa** (ZJ10611) at 100 pM in PBS with varying concentrations of the HER2 protein. Data points are shown as grey circles; each represents the average of three wells; the three panels represent replicate data collected on three separate occasions.




Figure S166. Fluorescence polarization data for unstapled affibody **fa8/42-xx** (ZJ10612) at 100 pM in PBS with varying concentrations of the HER2 protein. Data points are shown as grey circles; each represents the average of three wells; the three panels represent replicate data collected on three separate occasions. The red line represents fit of the data to a binding curve given by equation S4.





Figure S167. Fluorescence polarization data of stapled affibody **fa8/42-x4x (ZJ1062)** at 100 pM protein concentration in PBS. Data points are shown as grey circles; each represents the average of three wells; the three panels represent replicate data collected on three separate occasions. The red line represents fit of the data to a binding curve given by equation S4.

8. Stapling between heterochiral residues

For monomeric helical peptide stapling crossing one helical turn or two, application of heterochiral residues can further enhance the stabilizing effect from stapling on α -helices, since the heterochiral residues are oriented toward to each other, adopting a more favorable geometry for crosslinking. The favorable geometry derived from the heterochiral residues has been applied to disulfide-bond-based stapling^{4, 5} and metathesis-based stapling^{6, 7} on monomeric helical peptides. We found that both the residue 27e and 29g' are oriented toward the same N-terminus direction of the coiled-coil heterodimer from the crystal structure. We wondered whether heterochiral residues at position 27e and 29g' will be more favorable for interhelical PEG stapling. Accordingly, we incorporated D-propargylglycine at e-position 27 on the acidic monomer, and L-propargylglycine at g-position 29' on the basic monomer to get heterodimer (*R,S*)-**d27e/29g'-xx** and its stapled counterpart (*R,S*)-**sd27e/29g'-x4x**. The stapled variant (*R,S*)-**d27e/29g'-xx** is -0.73 ± 0.04 kcal/mol more stable than its non-stapled counterpart (*R,S*)-**d27e/29g'-xx**, which is similar to that of the difference between **d27e/29g'-xx** vs. **sd27e/29g'-x4x**, in which L-propargylglycine was incorporated at both position 27e and 29g', indicating that stapling between residues of opposite chirality residues dose not contribute much stabilization to the impact of interhelical PEG stapling.

9. Synthesis and Characterization of PEGylated Asparagine Derivatives, bis-azido PEG, branched Y-shaped bis-azido PEG

Oxybis(ethane-2,1-diyl) dimethanesulfonate (QX2227)



Methanesulfonyl chloride (14.3 g, 125 mmol) was added dropwise to a stirred solution of 2,2'-oxybis(ethan-1-ol) (5.3 g, 50 mmol) and triethyl amine (15.2 g, 150 mmol) in dichloromethane (200 mL) at 0 °C. After the

addition was complete, the resulting mixture was stirred at r.t. for 12 hrs. Water was added to quench the reaction. The organic phase was separated, and the aqueous phase was extracted with dichloromethane (2×100 mL). The combined organic layers were washed with brine (3×100 mL), dried with anhydrous sodium sulfate, filtered, and the solvent was removed by rotary evaporation to afford 13.1 g of colorless oil, which was used in the next step without purification. Yield quantitative. MS(ESI-TOF) m/z calc. for $C_6H_{15}O_7S_2^+$ 263.03, found 263.02 $[M+H^+]$; calc. for $C_6H_{18}NO_7S_2^+$ 280.05, found 280.05 $[M+NH_4^+]$.





Figure S168. ESI-TOF MS data for QX2227.

1-Azido-2-(2-azidoethoxy)ethane (QX2228)



To a solution of NaN_3 (9.7 g, 150 mmol) in DMF (200 mL) was added QX2227 (13.1 g, 50 mmol) at room temperature. The reaction mixture was heated to $70\text{ }^\circ\text{C}$ and stirred for 12 hours. The crude mixture was diluted with 400 mL of water and extracted with DCM (200 mL) for 3 times. The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate, filtered, and the solvent was removed by rotary evaporation to afford 8.32 g of yellow oil. Yield quantitative. The crude product was used in the next step without further purification. The product was confirmed by Crude NMR: $^1\text{H-NMR}$ (300 MHz, Chloroform- d) δ 3.71 (t, $J = 4.8$ Hz, 4H), 3.44 (t, $J = 4.8$ Hz, 4H). $^{13}\text{C-NMR}$ (126 MHz, Chloroform- d) δ 70.10, 50.76.




Figure S169. ^1H NMR data for QX2228.




Figure S170. ^{13}C NMR data for QX2228.





Figure S171. HSQC data for QX2228.

2-(2-Azidoethoxy)ethan-1-amine (QX2229)



Triphenylphosphine (11 g, 45 mmol, 0.9 eq.) dissolved in ether (80 mL) was added to a solution of QX2228 (8.32 g, 50 mmol) in Ether/THF/ 1M aqueous HCl (50 mL/100 mL/50mL). Addition was performed over a period of 3 hours at room temperature and the reaction was stirred overnight. Phases were separated by a separation funnel and the organic layer was washed with 4M HCl aqueous solution. The combined aqueous layer was adjusted to pH 14 with sodium hydroxide powder. Product was then extracted with DCM (3 × 80 mL). Combined organic layer was dried over anhydrous sodium sulfate and filtered. After removal of the solvent under reduced pressure, a yellow oil was afforded (4.3 g, yield 66%), which was used in the next step without purification. MS(ESI-TOF) m/z calc. for $\text{C}_4\text{H}_{11}\text{N}_4\text{O}^+$ 131.09, found 131.09 $[\text{M}+\text{H}^+]$.




Figure S172. ESI-TOF MS data for QX2229.




Figure S175. ^{13}C NMR data for QX2230.





Figure S176. HSQC data for QX2230.

N²-(((9H-fluoren-9-yl)methoxy)carbonyl)-N⁴-(2-(2-azidoethoxy)ethyl)-L-asparagine (QX2232)



Compound QX2230 (1.0 g, 1.9 mmol) was dissolved in a mixture of TFA (3 ml) and water (150 μ L). Then the reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction, TFA and water were removed by rotary evaporation. Yield quantitative. The crude was used directly for peptide synthesis without purification. MS(ESI-TOF) m/z calc. for C₂₃H₂₇N₅O₆⁺ 469.20, found 469.19 [M+H⁺].





Figure S177. ESI-TOF MS data for QX2232.

2,5-Dioxopyrrolidin-1-yl (2,5,8,11-tetraoxatridecan-13-yl) carbonate (QX3065)



To a solution of 2,5,8,11-tetraoxatridecan-13-ol (2.08 g, 10 mmol), and bis(2,5-dioxopyrrolidin-1-yl) carbonate (3.84 g, 15 mmol), was added 4.16 mL (30 mmol) TEA. The resulting solution was stirred at r.t. for 3 hours. After the reaction was completed, monitored by TLC, the ACN solvent was removed and 100 mL DCM was added. Then the solution was washed with 5% sodium bicarbonate (50 mL \times 3) then with water (50 mL \times 2). The organic layer was then dried over sodium sulfate, filtered, and evaporated with reduced pressure to give us the crude product as colorless oil. Yield quantitative. The crude was used in the next step without purification. MS(ESI-TOF) m/z calc. for $C_{14}H_{24}NO_9^+$ 350.14, found 350.15 $[M+H^+]$; calc. for $C_{14}H_{27}N_2O_9^+$ 367.17, found 367.17 $[M+NH_4^+]$.





Figure S178. ESI-TOF MS data for QX3065.

2,2'-((Azanediylbis(ethane-2,1-diyl))bis(oxy))bis(ethan-1-ol) (QX3061)



Add a solution of 2-(2-chloroethoxy)ethanol (6.4 mL, 60 mmol) in toluene (15 mL) dropwise to a stirred refluxing mixture of 2-(2-aminoethoxy)ethanol (24 mL, 240 mmol) and Na_2CO_3 (7 g, 66 mmol) in toluene (150 mL) in a flask fitted with Dean-Stark apparatus. Then the mixture was heated to 120 Celsius degree for 4 days. The solids were removed by filtration after the mixture was cooled to room temperature. The residue was washed by ether and the combined filtrates were concentrated in vacuo. The crude residue was purified by distillation. MS(ESI-TOF) m/z calc. for $C_8H_{20}NO_4^+$ 194.14, found 194.14 $[M+H^+]$. 1H NMR (300 MHz, Chloroform-*d*) δ 3.72 (t, J = 4 Hz, 4H), 3.66-3.60 (m, 8H), 2.86 (t, J = 5.1 Hz, 1H). ^{13}C NMR (126 MHz, Chloroform-*d*) 72.71, 69.79, 61.63, 48.94.




Figure S179. ESI-TOF MS data for QX3061.




Figure S180. ¹H NMR data for QX3061.




Figure S181. ¹³C NMR for QX3061.





Figure S182. HSQC for QX3061.

15-Oxo-16-(2-(2-(tosyloxy)ethoxy)ethyl)-2,5,8,11,14,19-hexaoxa-16-azahenicosan-21-yl 4-methylbenzenesulfonate (QX3072)



QX3065 (525 mg, 1.5 mmol) was added to a mixture of QX3061 (193 mg, 1.0 mmol) and TEA (415 μ L, 3.0 mmol) in DCM (5 mL) at room temperature. Then the mixture was stirred at room temperature for 12 hours. Then additional TEA (276 μ L, 2.0 mmol) was added to the mixture followed by 762 mg of TsCl (4.0 mmol). The reaction was stirred at room temperature for another 18 hours. Then the reaction was quenched with water, and the organic layer was further washed with sodium bicarbonate (5%) and brine. The crude was purified by chromatography (pure EA as mobile phase). MS(ESI-TOF) m/z calc. for $C_{32}H_{52}N_2O_{14}S_2^+$ 753.29, found 753.29 $[M+NH_4^+]$. 1H NMR (300 MHz, Chloroform- d) δ 7.82 (t, J = 8.1 Hz, 4H), 7.37 (t, J = 8.1 Hz, 4H), 4.23 (t, J = 5.1 Hz, 2H), 4.16 (t, J = 4.5 Hz, 4H), 3.71-3.65 (m, 16H), 3.58-3.52 (m, 6H), 3.42 (t, J = 5.4 Hz, 4H), 3.40 (s, 3H) 2.47 (s, 6H). ^{13}C NMR (126 MHz, Chloroform- d) 156.05, 144.90, 132.93, 129.91, 127.97, 71.94, 70.61, 70.59, 70.54, 70.44, 70.01, 69.72, 69.51, 69.24, 68.44, 68.34, 67.45, 59.07, 48.20, 47.75, 21.69.




Figure S183. ESI-TOF MS data for QX3072.




Figure S184. ¹H NMR data for QX3072.




Figure S185. ¹³C NMR data for QX3072





Figure S186. HSQC data for QX3072.

2,5,8,11-Tetraoxatridecan-13-yl bis(2-(2-azidoethoxy)ethyl)carbamate (QX3075)



To a solution of NaN_3 (77 mg, 1.2 mmol) in DMF (2 mL) was added QX3072 (219 mg, 0.29 mmol) at room temperature. The reaction mixture was heated to 70 Celsius degree and stirred for 12 hours. The crude mixture was diluted with 4 mL of water and extracted with DCM (2 mL) for 3 times. The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate, filtered, and the solvent was removed by rotary evaporation to afford 138 mg of product as colorless oil. Yield quantitative. MS(ESI-TOF) m/z calc. for $\text{C}_{18}\text{H}_{39}\text{N}_8\text{O}_8^+$ 495.29, found 495.29 $[\text{M}+\text{NH}_4^+]$. ^1H NMR (300 MHz, Chloroform-*d*) δ 4.23 (t, $J = 5.1$ Hz, 2H), 3.69 (t, $J = 4.5$ Hz, 2H), 3.66-3.61 (m, 18H), 3.55-3.54 (m, 6H), 3.38 (s, 3H), 3.37-3.35 (m, 4H), ^{13}C NMR (126 MHz, Chloroform-*d*) 156.05, 71.93, 70.61, 70.53, 70.44, 69.92, 69.86, 69.78, 69.66, 69.53, 64.41, 59.03, 50.77, 48.37, 47.94.




Figure S187. ESI-TOF MS data for QX3075.




Figure S188. ¹H NMR data for QX3075.




Figure S189. ¹³C NMR data for QX3075.




Figure S190. HSQC data for QX3075.

ESI References

1. Q. Xiao, D. S. Ashton, Z. B. Jones, K. P. Thompson and J. L. Price, *RSC Chem. Biol.*, 2020, **1**, 273–280.
2. P. B. Lawrence, Y. Gavrillov, S. S. Matthews, M. I. Langlois, D. Shental-Bechor, H. M. Greenblatt, B. K. Pandey, M. S. Smith, R. Paxman, C. D. Torgerson, J. P. Merrell, C. C. Ritz, M. B. Prigozhin, Y. Levy and J. L. Price, *J Am Chem Soc*, 2014, **136**, 17547-17560.
3. M. S. Smith, W. M. Billings, F. G. Whitby, M. B. Miller and J. L. Price, *Org. Biomol. Chem.*, 2017, **15**, 5882–5886.
4. D. Y. Jackson, D. S. King, J. Chmielewski, S. Singh and P. G. Schultz, *Journal of the American Chemical Society*, 1991, **113**, 9391-9392.
5. A. M. Leduc, J. O. Trent, J. L. Wittliff, K. S. Bramlett, S. L. Briggs, N. Y. Chirgadze, Y. Wang, T. P. Burris and A. F. Spatola, *P Natl Acad Sci USA*, 2003, **100**, 11273-11278.
6. C. E. Schafmeister, J. Po and G. L. Verdine, *Journal of the American Chemical Society*, 2000, **122**, 5891-5892.
7. L. D. Walensky, A. L. Kung, I. Escher, T. J. Malia, S. Barbuto, R. D. Wright, G. Wagner, G. L. Verdine and S. J. Korsmeyer, *Science*, 2004, **305**, 1466-1470.